



Please download and read the [Referee Guidelines](#)

## Intravenous immunoglobulin: pharmacological properties and use in polyneuropathies

Journal:	<i>Expert Opinion On Drug Metabolism and Toxicology</i>
Manuscript ID	EOMT-2016-0106.R1
Manuscript Type:	Review
Keywords:	IVIg, CIDP, GBS, anti-idiotypic antibodies, anti-ganglioside antibodies, sialylation, IgG molecule., Fc receptors

SCHOLARONE™  
Manuscripts

**Abstract**

Introduction: Intravenous immunoglobulin (IVIg) is increasingly used for the treatment of autoimmune and systemic inflammatory diseases with both licensed and off-label indications. The mechanism of action is complex and not fully understood, involving the neutralization of pathological antibodies, Fc receptor blockade, complement inhibition, immunoregulation of dendritic cells, B cells and T cells and the modulation of apoptosis.

Areas covered: First, this review describes the pharmacological properties of IVIg, including the composition, mechanism of action, and adverse events. The second part gives an overview of some of the immune-mediated polyneuropathies, with special focus on the pathomechanism and clinical trials assessing the efficacy of IVIg. A literature search on PubMed was performed using the terms IVIg, IVIg preparations, side effects, mechanism of action, clinical trials, GBS, CIDP.

Expert opinion: Challenges associated with IVIg therapy and the treatment possibilities for immune-mediated polyneuropathies are discussed. The availability of IVIg is limited, the expenses are high, and, in several diseases, a chronic therapy is necessary to maintain the immunomodulatory effect. The better understanding of the mechanism of action of IVIg could open the possibility of the development of disease-specific, targeted immune therapies.

**Keywords:** IVIg, CIDP, GBS, anti-idiotypic antibodies, anti-ganglioside antibodies, sialylation, IgG molecule, Fc receptors.

# Intravenous immunoglobulin: pharmacological properties and use in polyneuropathies

## 1. Introduction

Intravenous immunoglobulin (IVIg) is prepared from plasma collected and pooled from several thousands of healthy donors. IVIg therapy was first used as a substitution therapy in primary and secondary immunodeficiencies [1]. In the early 1980s, Imbach successfully used high doses of polyclonal IgG to treat immune thrombocytopenic purpura (ITP) in children with immune deficiency [2]. Since then, the spectrum of autoimmune diseases treated with IVIg has been expanding continuously. Besides the licensed indications that can vary from country to country depending on the local regulatory authorities, several off-label indications exist covering hematological, dermatological, neurological, and oncological indications. The list of diseases that can be treated with IVIg is presented in Table 1 [3, 4].

This review includes a description of the composition, pharmacokinetics, and mechanisms of action of IVIg. The second part of the paper provides an overview of the immune-mediated polyneuropathies in which IVIg is a first-line therapy, with special focus on the pathomechanism of the diseases, the mechanisms of action of IVIg, and of the main results of clinical trials supporting the evidence of its efficacy.

## 2. Composition of IVIg

IVIg is a complex preparation pooled from a minimum of 1000 and up to 60,000 donors, depending on the manufacturer [5], which contains antibodies against a multitude of antigens. As a result of pooling, a diversity of antibody specificities is obtained. IVIg predominantly contains polyclonal immunoglobulin G (IgG), and low quantities of IgA and IgM. The IgG molecule comprises two heavy and two light chains (Figure 1). Both chain types have hypervariable regions that form the antigen-binding sites (Fab). When exposed to an antigen, B cells with complementary binding sites are selected and stimulated to secrete antibodies against the antigen. These antibodies

1 themselves function as an antigen. The unique antigen-binding site is called the *idiotype*, whereas  
2 the antibody secreted against the idiotype and capable of blocking it is referred to as the *anti-*  
3 *idiotype* [6, 7]. The anti-idiotypes can block the antigen-binding site of the pathological antibody.  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

At first, IVIg was used in a concentration of 5%, but subsequently, formulations with higher concentrations of 10-12% were also developed, which permitted the lowering of the volume load and the shortening of the time of administration. Formulations for subcutaneous use (**SCIg**) are available since the 1980s, which permit steadier IgG levels and a more favorable systemic side effect profile, **except for the higher incidence of local reactions**. Several brands of IVIg are available, with each considered to be a distinct product with a unique composition and different excipients. The products differ with regard to the production process, viral inactivation, purification, IgA content, **sodium content**, and the applied stabilizers, and are associated with different risks of adverse effects, depending predominantly on the IgA content, the osmolarity, and the stabilizers used.

**In recent years, significant advances have been achieved in the production process of IVIg preparations with regard to purity, pathogen inactivation, and stabilization. Cold alcohol fractionation is used to isolate the immunoglobulin-containing plasma fraction, which is further purified through multiple steps of precipitation and can also be combined with ion-exchange chromatography, processes resulting in a highly purified polyvalent IgG product (>95%). Pathogens are removed by manipulations including fatty acid/alcohol treatment, low pH, solvent-detergent treatment, pasteurization, and nanofiltration. Beside maltose, sucrose, and glucose, amino acids such as glycine and proline can also be used as stabilizers [10].**

**The liquid products and the reconstituted solutions of lyophilized products are stored in refrigerators, and are to be brought to room temperature before use. Microwave and other heating procedures are not recommended, as they can denature the product. Shaking and**

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**mixing should be avoided, as they can cause excessive foaming. The product should be carefully inspected before use to avoid administration of a solution that is not completely dissolved and contains visible particles and aggregates [10].**

There are insufficient data on the efficacy and the cost-effectiveness from head-to-head randomized clinical trials to prove the superiority of one brand over the other; therefore, the choice of the brand in the daily practice depends on the characteristics of the product and the risk factors of the particular patient [5].

**The choice of route of administration should be based on the clinical setting. It depends on the clinical characteristics of the patient, the preference of the patient, the site of care, the experience of the medical staff, and insurance coverage [11]. Although in immunodeficiencies, SCIG and IVIg are both approved (a.k.a. 'on-label') therapies, in autoimmune diseases, particularly in inflammatory neuropathies, IVIg is the preferred product, presumably due to the fact that it was more extensively studied and its efficacy is evidence-based. Notably, however, the results of some clinical trials with SCIG are promising [12].**

### 3. Pharmacokinetics

The dose of IVIg used for the treatment of immunodeficient conditions is 0.4–0.6 g/kg, administered every 3 to 4 weeks. Once the diagnosis is set, a continuous replacement therapy is to be initiated, which should not be interrupted. Some patients require higher doses of up to 0.8 g/kg. Doses exceeding this level have not been evaluated [13]. The total dose used in autoimmune/inflammatory diseases is 2 g/kg, administered in 2-5 consecutive days. This dose was introduced to clinical practice after the observation of a dramatic increase in the platelet count in a patient with concomitant immunodeficiency and ITP [2]. The initial dose is followed by maintenance infusions in doses of 1-2 g/kg every 3-4 weeks. The doses are generally adjusted according to the clinical response, and no antibody measurements are used. Individualized therapy is needed for each patient with respect to the applied doses (g/kg/month) and the intervals of

1 administration.

2  
3  
4 Intravenous infusion in a dose of 2 g/kg results in a 4-fold increase in the serum IgG levels.  
5  
6 After 48-72 hours, the serum IgG levels drop by 50% as a result of the distribution in the  
7  
8 extracellular fluid [14]. IgG is then catabolized and has a half-life (T1/2) of maximum 21-30 days,  
9  
10 depending upon the activity of the neonatal Fc receptors (FcRns) [15]. At low pH conditions,  
11  
12 circulating IgG in the serum is endocytosed by myeloid cells and endothelial cells, bound to FcRns  
13  
14 and recycled to the surface of the cells [16].  
15  
16

17 The IVIg antibodies compete with pathological autoantibodies for the FcRn binding sites.  
18  
19 Animal models of immune disorders, such as that of ITP and bullous pemphigoid, show a reduction  
20  
21 of the T1/2 of pathological autoantibodies after IVIg infusion [17, 18]; however, it is unclear to  
22  
23 what extent this phenomenon is responsible for the anti-inflammatory effect of IVIg preparations.  
24  
25 The exact role of FcRns in the therapeutic effect of IVIg is difficult to estimate. The reduction of the  
26  
27 FcRns observed in experimental conditions in FcRn-deficient animals leads to a subsequent  
28  
29 reduction in the T1/2 of autoantibodies, and interferes with the mechanisms leading to tissue  
30  
31 inflammation; on the other hand, however, the T1/2 of IVIg preparations is also decreased in these  
32  
33 animal models [16].  
34  
35  
36  
37  
38  
39

#### 40 **4. Pharmacodynamics - mechanism of action**

41 The immunomodulatory mechanism of action of IVIg has not yet been fully elucidated.  
42  
43 Several mechanisms have been proposed (Figure 2), some of which are presumed to be mediated  
44  
45 through the binding of the constant fragment (Fc) to Fc $\gamma$  receptors (Fc $\gamma$ Rs) on the target cells,  
46  
47 whereas other proposed mechanisms are mediated by the variable (Fab) region of the IgG. Some of  
48  
49 these mechanisms are dose-dependent and are attributed to a competition with pathological  
50  
51 antibodies, whereas others are more complex and involve cellular networks and various molecular  
52  
53 targets.  
54  
55  
56  
57  
58  
59  
60

#### **4.1. Fc pathway-mediated immunomodulatory effects of IVIg**

The Fc fragment is essential for the initiation of inflammation and acts as an adaptor, linking the innate and adaptive immune responses. The innate humoral response is triggered by the activation of complement 1q (C1q) and that of the innate immune cells via the Fc $\gamma$ Rs. The Fc $\gamma$ R family contains one inhibitory and several activating members, and an alteration of their balanced expression or function may result in inflammation [19]. IVIg modulates the expression of the inhibitory Fc $\gamma$ Rs and blocks the activating Fc $\gamma$ Rs on antigen presenting cells (APCs). Fc $\gamma$ Rs have a low affinity for monomeric IgG and can be better activated by multimeric IgG, such as that present in immune complexes. However, there are no IgG aggregates in IVIg preparations, and the proportion of IgG dimers is also low. The small relative amount of dimers and the low affinity of the receptors might be responsible for the high doses of IVIg required to achieve an immunosuppressive effect [8].

**Dimers that occur in IVIg preparations are formed by idiotype-anti-idiotype antibody pairs, for which the site of interaction is localized to the distal part of the Fab fragments [20]. The content of dimers in IVIg preparations depends on age, the formulation, the stabilizers used, and the conditions of storage, and it varies between 5 and 15% [21]. An increased level of dimers in the IVIg preparations correlates with a higher incidence of side-effects [21, 22]. Experiments have demonstrated that dimers have increased self-reactive specificities compared to those of the monomeric fraction, and some of these antibodies are of value for the treatment of autoimmune and inflammatory diseases [22]. In CIDP patients, IVIg infusion has been evidenced to increase the serum dimer levels to an extent suggesting a spontaneous formation of new immune complexes. These newly formed dimers show immunoreactivity against peripheral axons and Schwann cells; however, the specific antigens could not be revealed yet. A high serum level of dimers detected following IVIg infusion correlates with a better clinical response to IVIg therapy, suggesting that post-infusion dimer levels might be used as biomarkers to identify IVIg responsive patients. Further analysis of dimers formed**

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**after IVIg infusion could identify disease-specific antibodies [21].**

The infusion of Fc $\gamma$  fragments alone can block Fc $\gamma$ Rs and increase the platelet count in ITP patients. Particularly sialylated Fc fragments with a terminal alfa 2-6 sialylation of the Fc glycan exert anti-inflammatory properties [23, 24]. In patients with SLE, lower levels of sialylated IgG (saIgG) are detected, a phenomenon which can serve as a biomarker of the disease [25]. The saIgG represents only 1-2% of the total IgG in the therapeutic preparations and has a low affinity for the Fc $\gamma$ Rs, suggesting that not the blockade of the Fc $\gamma$ Rs but rather an action on other receptors is responsible for the inhibitory effect. Examples of such receptors are members of the sialic acid-binding immunoglobulin-like lectin (SIGLEC) receptor family, including the cluster of differentiation-22 (CD22) inhibitory receptor on B cells. These receptors have motifs capable of triggering cell inactivation, such as the intracellular immunoreceptor tyrosine-based inhibitory motifs (ITIMs) or ITIM-like motifs [8, 9, 26]. The saIVIg interacts with adhesion molecules (specific intercellular adhesion molecule-3-grabbing non-integrin, SIGN) on dendritic cells (DCs) and macrophages, leading to the overexpression of the inhibitory Fc $\gamma$  RIIB and to a consequent stimulation of the immunosuppressive regulatory T cells (Tregs) [27]. Experimental evidence confirms that saIVIg Fc provides a protective effect in T cell-mediated and antibody-mediated autoimmune diseases [26]. Sialylation might induce conformational changes in IgG molecules that decrease the binding affinity to Fc $\gamma$ Rs, but increase that to other receptors, such as SIGNs [28, 29].

**Recent studies have questioned the role of the Fc $\gamma$ RIIBs as well as of the sialylation of the Fc fragments in the anti-inflammatory effects of IVIg. A proposed mechanism based on experience from animal models postulates that sialylated Fc fragments may act on DC-SIGN receptors and promote the release of IL-33, a molecule which stimulates basophils that produce IL-4. The therapeutic effect of IVIg and the role of Fc fragments have been confirmed in a murine arthritis-model; however, the results did not support the involvement of sialylation or that of the basophils in the mechanism of action of IVIg therapy [30]. In line with this, in rheumatic patients, IVIg induced the release of IL-33, which was, however, not**



1 associated with the stimulation of basophils, and IL-4 could be hardly detected in the plasma  
2 of patients following IVIg therapy. The source of IL-33 was unclear, as its production could  
3 not be shown from DC-SIGN+ human innate cells. These results suggest that the therapeutic  
4 effect of IVIg is independent of sialylation and basophils [31]. In an *in vitro* study on human  
5 macrophages, the IVIg-induced inhibition of the phagocytosis of IgG-opsonized blood cells  
6 was independent of Fc sialylation and the upregulation of the FcγRIIBs, but improved when  
7 preparations with an increased binding capacity to the low-affinity FcγRs, such as the IgG  
8 dimers, were used [32].  
9  
10 The regulatory action on T cells and the effect on cytokines are presumed to be likewise  
11 sialylation-independent [33, 34].  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23

#### 24 4.2. Fc-independent mechanisms of action of IVIg

25  
26 Mechanisms independent of the Fc pathway have also been proposed underlying the  
27 therapeutic action of IVIg; however, a co-operation of Fab and Fc regions in these mechanisms  
28 cannot be fully excluded.  
29  
30  
31

##### 32 *4.2.1. Anti-idiotypic antibodies*

33  
34  
35 Antibodies in the IVIg preparations can neutralize toxins and pathogens as well as  
36 pathogenic antibodies with their F(ab') portion. *In vitro* experiments demonstrate that F(ab') or  
37 F(ab')<sub>2</sub> IVIg fragments *per se* can neutralize autoantibodies. The anti-idiotypic antibodies present in  
38 the IVIg preparations can neutralize pathological antibodies such as the anti-ganglioside antibodies  
39 in **Guillain-Barré syndrome** (GBS) and chronic inflammatory demyelinating polyneuropathy  
40 (CIDP), and the anti-acetylcholine receptor antibodies in myasthenia gravis. In certain autoimmune  
41 disorders with a deficiency in the idiotypic network, IVIg therapy can restore the normal function.  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
The idiotypic-anti-idiotypic interaction may presumably be a mechanism through which IVIg  
modifies the autoimmune disease process. The amount of anti-idiotypic antibodies is very low in the  
IVIg preparations, suggesting the involvement of other more complex mechanisms in addition to a  
neutralizing action, such as an immune-modulating function or an inhibitory effect on B cells

1 through Fc $\gamma$ IIRBs [7].

#### 2 3 4 4.2.2. *Anti-complement effect*

5 Soluble IgG from the IVIg preparation competes with surface-bound IgG for C3b, and  
6 thereby inhibits the complement-mediated lysis of the target cells. This is of importance in  
7 complement-mediated diseases, such as GBS [35]. In dermatomyositis, IVIg forms complexes with  
8 C3 and hence prevents its activation. As a result, it prevents the formation of the C5b/C9 membrane  
9 attack complex (MAC) responsible for the inflammation of intramuscular capillaries [15].  
10 Reductions in the expression of intercellular adhesion molecule (ICAM) and major  
11 histocompatibility complex (MHC) I were observed following IVIg treatment, and a down-  
12 regulation of cytokines, complement factors, and adhesion molecules was evidenced as well. IgG  
13 can also non-covalently bind to C3a and C5a, which results in the diminishment of the pro-  
14 inflammatory effects [36].  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27

28 IVIg is capable of neutralizing anaphylatoxins, such as C3a and C5a, and of suppressing the  
29 complement-induced release of pro-inflammatory thromboxane B2 and histamine. The  
30 neutralization of C3a and C5a was observed to occur in cells treated with Fab and whole IVIg, and  
31 was found to be independent of the Fc $\gamma$  fragments. In fact, both the F(ab')<sub>2</sub> and the Fc fragments  
32 play roles in complement inhibition. C3b and C5b bind to the Fc region, whereas C3a and C5a are  
33 neutralized by the F(ab')<sub>2</sub> fragments present in the IVIg, with the latter resulting in the inhibition of  
34 MAC formation and a subsequent damage to the target tissue [37].  
35  
36  
37  
38  
39  
40  
41  
42  
43

#### 44 4.2.3. *Cell-penetrating antibodies*

45 In addition to an FcR-mediated endocytosis, IVIg can be internalized also in an FcR-  
46 independent manner by immune cells. Cell-penetrating antibodies (CPAs) are known to play roles  
47 in certain autoimmune diseases. Among them, the anti-nuclear CPAs in SLE are capable of inducing  
48 apoptosis and modulating the expression of nuclear factors and cytokines [38]. However, a recent  
49 study showed that IgG present in the IVIg preparations can penetrate into a variety of cell lines in  
50 an energy-independent manner, in a process mediated by the F(ab') fragment. Up to 2% of IgGs in  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

IVIg have been demonstrated to be CPAs. These natural CPAs might modulate cellular activities; however, their exact role is still incompletely understood, necessitating further investigations [39].

#### **4.3. IVIg alters dendritic cell and regulatory T cell function**

IVIg can inhibit the maturation and differentiation of DCs and induces tolerogenic phenotypes, an effect mediated by both the Fab and the Fc fragments. The mechanism through which these effects occur have not yet been completely elucidated. IVIg is presumed to activate Fc $\gamma$ R by triggering the immunoreceptor tyrosine-based activation motif (ITAM). The presence of Fc $\gamma$ RIIB inhibitory receptors was found to be indispensable for these effects of IVIg in different autoimmune disorders. No interaction exists between this receptor and IVIg; however, the upregulation of the Fc $\gamma$ RIIB on DCs and APCs is essential for the suppressive effect of IVIg on DC activation [40].

Tolerogenic DCs express a low amount of co-stimulatory molecules (CD40, CD80, and CD86), and are characterized by a reduced expression of MHC class II (and thereby a decreased ability to present antigens), an increased expression of co-inhibitory molecules (PD-L1, CTLA-4), and an increased production of inhibitory cytokines [41]. DCs present antigens to T cells. Naive T cells are induced via cell-cell contact and by soluble mediators provided by an APC, and receive signals via the T cell receptors (TCRs), costimulatory molecules, and cytokine receptors [26]. DCs act on naive T cells and induce their evolution into distinct T cell subsets. In animal experiments, IVIg inhibits the differentiation of CD4<sup>+</sup> cells to T helper 1 (Th1) and Th17 cells, and induces an expansion of the immune-suppressor Treg cells [42-44]. Polyclonal IVIg predominantly targets CD11c<sup>+</sup> DCs, a mechanism demonstrated to be sufficient for the peripheral induction of Tregs in IVIg-treated mice [45].

Tregs maintain tolerance to self-antigens and preserve the homeostasis of the immune system. Two main types of Tregs are distinguished: naturally occurring Tregs (nTregs), generated in the thymus, and peripherally induced Tregs (pTregs), originating in peripheral lymphoid tissues from CD4<sup>+</sup> cells. Tregs express specific markers. The transcription factor, forkhead box P3

(FOXP3), provides anti-inflammatory functions and its expression enables the switch of T cells towards a regulatory phenotype. Other markers include CD25 (a high-affinity interleukin-2 (IL-2) receptor), human leukocyte antigen-DR (HLA-DR), CTLA-4, GARP, TIGIT, a CD28-related protein, and Fc receptor-like protein 3 (FCRL3; an Fc-receptor-like glycoprotein) [46].

IVIg administration increases the number as well as the suppressive function of Tregs. Treg induction by IVIg can be explained by a direct interaction of IgG with T cells and with other targets, such as APCs and cytokines. In cell cultures, IVIg increases the expression of FOXP3 [47, 48]; furthermore, epitopes from both the Fc and Fab fragments (Tregitopes) can activate FOXP3, resulting in Treg activation and expansion [49]. The prostaglandin E (PGE) pathway might also play a role in the IVIg-induced changes in Treg function, **as the IVIg-induced increase in the number of Tregs is associated with an increase in circulating PGE2 levels. PGE2 can inhibit natural killer (NK) cells, granulocytes, and macrophages, and impairs the ability of DCs to stimulate Th1 cells. PGE2 induces the expansion of Tregs and improves their immunosuppressive function [50].** Tregs can provide immunological tolerance in autoimmune diseases; however, Treg infusion therapy has not yet been successfully implemented; therefore, therapies targeting Treg expansion and activation are of increasing interest [51]. **The reciprocal regulation between the inhibition of Th1 and Th17 cells and the expansion of FOXP3+ Treg cells is independent of sialylation, according to results gained from an experimental autoimmune encephalitis (EAE) model [33]. Th17 cell expansion and activation might be inhibited by the Fab fragments, which could also induce Treg expansion through PGE2 [33]. In cell culture, IVIg and SCIg exerted inhibitory effects on T cell activation and suppressed several effector cytokines; however, these effects did not require sialylation and were independent of B cells or monocytes [34].**

#### **4.4. Effects on cytokines and chemokines**

IVIg exerts anti-inflammatory effect through a modulation of the production of cytokines and cytokine antagonists [52]. IVIg modulates cytokine production in monocytes, but also acts on T

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

helper cell types (Th1, Th2, and Th17). IVIg upregulates the production of inhibitory cytokine IL-10 in DCs, and downregulates pro-inflammatory cytokines, such as interferon- $\gamma$  (IFN $\gamma$ ), tumor necrosis factor- $\alpha$  (TNF $\alpha$ ), and IL-12 [53]. IVIg also acts on chemokines and influences chemokine receptor expression on circulating leukocytes, contributing to the homeostasis, recruitment and trafficking of inflammatory cells, including Tregs, to different tissues. IVIg treatment results in the downregulation of ICAM-1, complement C1q, IL-22, transforming growth factor-1 (TGF-1), and the upregulation of the chemokines, CXCL11 and CXCL and a number of immunoregulatory genes [52].

#### **4.5. Effects on apoptosis**

IVIg can inhibit cell activation and can even induce apoptosis in various different types of immune cells, including macrophages, NK cells, DCs, and T and B lymphocytes [54]. IVIg preparations contain agonist and antagonist antibodies to the CD95 receptor, and their effect proved to be dose-dependent in *in vitro* studies. While low doses inhibit CD95-mediated neutrophil apoptosis, the high doses induce it [55]. Anti-CD95 antibodies presumably have an immunomodulatory effect that depends on the applied IVIg dose, probably on the disease state, as well as on the proportion and avidity of the agonistic and antagonistic antibodies [56].

### **5. Adverse events and safety considerations**

Adverse events are related to IVIg antigenicity, traces of IgA, the presence of aggregates, pathogenic antibodies, and molecules not removed during fractionation, such as procoagulants or kallikreins, and to the applied stabilizers. The side effect profile varies from one brand to another. Adverse events can be classified according to the localization (local and systemic), the severity (mild, moderate, and severe), as well as the occurrence (immediate, delayed, and late) [57]. See also Table 3.

Local side effects are rare, whereas systemic side effects occur in 20-40% of patients and 5-

1 15% of infusions [58], with higher rates (55% and 18% respectively) observed in doses of 1-2 g/kg  
2  
3 [59].

4  
5  
6 Immediate side effects occur within 6 hours and are usually mild, with the exception of  
7  
8 anaphylactic/anaphylactoid reactions, which can be life-threatening. Delayed reactions occur within  
9  
10 1 week, whereas late reactions, such as infections and interference with vaccine effectiveness,  
11  
12 develop weeks or months after the infusions [57].

13  
14 Side effects are mostly transient and mild, estimated to occur between 1 to 15% of infusions,  
15  
16 and many of them can be reversed even by temporarily stopping or slowing the infusion [60]. The  
17  
18 most frequently encountered adverse effects include headache, chills and fever, nausea, mild  
19  
20 hypotension or hypertension, and mild arthralgias. According to a meta-analysis of randomized  
21  
22 trials, headache, chills, fever, and nausea were reported in 82 out of 167 IVIg-treated participants,  
23  
24 corresponding to a 49% of side effect rate, a frequency statistically indifferent from that observed in  
25  
26 the groups treated with prednisolone or plasma exchange (PE). The severe side effects include  
27  
28 aseptic meningitis, anaphylactic shock, thrombosis, stroke, and impairment of renal function. The  
29  
30 incidence of severe adverse events was less than 0.5% for 26,000 infusions, and less than 4% in  
31  
32 2554 participants in a postmarketing pharmacovigilance study [61]. In randomized trials, the  
33  
34 occurrence of serious side effects was 6%, and was not statistically significant as compared to that  
35  
36 encountered in participants treated with prednisolone (7%), PE (12%), or placebo (7%). It is  
37  
38 difficult to compare the side effects of different therapeutic regimens in clinical trials, as patients  
39  
40 treated with PE are less in number compared to those treated with IVIg, rendering the results less  
41  
42 accurate. On the other hand, most of the trials were not designed long enough for steroid-related  
43  
44 side effects to develop [62].

### 45 46 47 48 49 **5.1. Safety considerations**

50  
51 Risk factors for IVIg-related thrombotic adverse events include advanced age,  
52  
53 immobilization, hyperviscosity, a history of arterial or venous thrombosis, the presence of  
54  
55 cardiovascular risk factors, and indwelling vascular catheters; however, thrombosis can occur even  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

in the absence of any apparent risk factors. Mechanisms underlying IVIg-related thrombosis include hyperviscosity and the presence of procoagulant antibodies or coagulation factors, such as activated factor XI, in the IVIg preparation [63, 64]. IVIg-related thrombosis is arterial in 80% of the cases, and occurs within hours to days [57]. Venous thrombotic adverse events, such as deep venous thrombosis or pulmonary embolism, generally develop days to weeks after infusion [65]; furthermore, the occurrence of cerebral venous sinus thrombosis has also been reported [66]. A proper hydration and the administration of IVIg at the minimum dose effective and the minimum rate of infusion practicable are factors essential in the prevention of IVIg-related thrombosis [67].

Patients with IgA deficiency and with antibodies to IgA are at risk to develop anaphylactic reactions and hypersensitivity due **to the IgA present in IVIg products. In the newer preparations, however, only traces of IgA are present, and this problem is less prevalent** [68].

Hemolytic anemia is an adverse event developing due to intravascular hemolysis or an enhanced sequestration of red blood cells, and is associated with risk factors such as higher doses of IVIg applied, the presence of an underlying inflammation, and a non-O blood group [69]. **In a review on five cases of GBS and MFS, all three patients with non-O blood group developed hemolytic anemia requiring blood transfusion. The authors concluded that in these patients, the risk of hemolytic anemia is increased when high doses of IVIg are administered over a short interval of less than 2 weeks** [70].

In predisposed patients, acute renal failure, renal dysfunction, and nephrosis may occur more commonly in case the preparation contains sucrose or maltose. Slow infusion rate, monitoring of renal function, and adequate hydration need to be ensured [71].

Aseptic meningitis has also been reported as an IVIg-related adverse event; however, it is usually mild and resolves without sequelae [72]. **PRES may occasionally occur after IVIg infusion [73, 74]. This condition should be suspected in patients developing visual disturbances, confusion, and seizures following IVIg infusion, and the diagnosis can be confirmed by MRI. In such cases, improvement was reported with PE therapy [75, 76].**

1  
2 Other possible side effects include vasospasm, vasculitis, enterocolitis, eczema,  
3  
4 hyperproteinemia, hyponatremia, and mild leukopenia [72]. IVIg is a plasma product and, therefore,  
5  
6 has the inherent potential risk of transmission of different infectious agents, such Parvovirus B19 or  
7  
8 the prion protein; however, no cases of the latter have so far been reported [77]. IVIg preparations  
9  
10 can influence the response to live virus vaccines. Though IVIg is not contraindicated in pregnant  
11  
12 women, it should be used with caution. Each IVIg preparation is a different compound, and the  
13  
14 safety considerations should be taken into account as regards the particular preparation.  
15  
16  
17  
18  
19

## 20 **6. Background and clinical evidence for the efficacy of IVIg in immune-mediated** 21 **polyneuropathies**

### 22 **6.1. Guillain-Barré syndrome**

#### 23 6.1.1. Clinical presentation.

24  
25  
26  
27  
28  
29  
30  
31 GBS is an acute ascending-type symmetrical sensorimotor polyneuropathy. The incidence is  
32  
33 0.81-1.89 per 100,000 person-year [78]. Most of the cases are characterized by demyelination,  
34  
35 termed acute inflammatory demyelinating polyneuropathy (AIDP), however, more severe axonal-  
36  
37 type variants also exist. See Table 4 for the classification of immune-mediated polyneuropathies  
38  
39 [79, 80]. Patients have predominantly motor signs, but pain and sensory impairments also  
40  
41 frequently occur. Up to 10-20% of patients have signs of cranial nerve involvement and a  
42  
43 comparable proportion of patients present with concomitant autonomic involvement, manifesting  
44  
45 predominantly in tachycardia, hypertension, rapid changes in blood pressure, bladder dysfunction,  
46  
47 and gastrointestinal dysfunction. Sudden death can also occur. The diagnosis is established on  
48  
49 clinical grounds, supported by electroneurography (ENG), which also yields the type of nerve  
50  
51 damage and, thereby, the subtype of GBS, and by the evidence of an elevated protein count without  
52  
53 pleocytosis in the cerebrospinal fluid (CSF), a phenomenon also referred to as *albuminocytologic*  
54  
55 *dissociation*. Serological evidence of the triggering infection and testing for anti-ganglioside  
56  
57  
58  
59  
60



1  
2 antibody also add to the diagnosis. The severity, the clinical course, and the outcome are variable,  
3  
4 and about 20% of patients remain with some extent of long-term disability. Although GBS is  
5  
6 considered a monophasic disease, about 5-10% of patients can succumb [79, 81].  
7  
8  
9

#### 10 6.1.2. Pathomechanism and mechanism of action of IVIg

11  
12 **The pathomechanism of GBS is complex and involves cellular and humoral**  
13 **mechanisms.** The presumed background of GBS is the *molecular mimicry*, induced by a pathogen.  
14  
15 Indeed, antibodies against *Campylobacter jejuni* or other pathogens, such as cytomegalovirus  
16  
17 (CMV), Epstein-Barr virus (EBV), *Mycoplasma pneumoniae*, or *Haemophilus influenzae*, have  
18  
19 been shown to cross-react with self-antigens [82, 83]. In a study, up to 43 % of patients had  
20  
21 serologic evidence of an infection [84]. Patients with a proper anti-idiotypic response can neutralize  
22  
23 the antigen-binding site of the antibodies secreted against the pathogen; however, patients with an  
24  
25 ineffective anti-idiotypic response will continue to produce antibodies that will cross-react with the  
26  
27 nerve tissue [15]. Antibodies against gangliosides have been detected in some 60% of GBS patients  
28  
29 with evidence of previous infections [84].  
30  
31  
32  
33  
34

35 Anti-GM1 and anti-GD1a antibodies were identified in acute motor axonal neuropathy  
36  
37 (AMAN) patients [85], whereas anti-GQ1b antibodies were found in 65% of acute ataxic form and  
38  
39 also in Miller Fisher syndrome (MFS) [86]. Antibodies against nodal proteins, such as neurofascin  
40  
41 (NF) and gliomedin, were identified in **some** AMAN and AIDP patients [87]. **NF has a neuronal**  
42  
43 **isoform (NF186) with a role in sodium channel clustering and a glial isoform (NF155)**  
44  
45 **necessary for paranodal junction formation. Autoantibodies to NF can be detected in some**  
46  
47 **4% of patients with AIDP and CIDP. Most antibodies are of IgG1, IgG3, and IgG4 subtypes**  
48  
49 **[88]. In 52 patients with GBS, the serum NF-IgG levels were significantly higher compared to**  
50  
51 **controls. NF antibodies are presumed to impair sodium channel function, disrupt axonal**  
52  
53 **conduction at the nodes, lead to axonal injury, and impair remyelination [89].** Anti-GM1  
54  
55 antibodies cause a reversible impairment of nodal function, affecting the axolemma. Antibodies  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

against Schwann cell antigens are presumed to be responsible for the classical GBS form, whereas antibodies against the axolemma are proposed to cause the axonal variants. The nodes of Ranvier may also be disrupted, thereby exposing axonal and myelin antigens, which lead to overlapping clinical forms. The binding of the pathogenic antibody is followed by complement activation and complement-mediated nerve cell damage [90]. **A decreased number and an altered function of Tregs are involved in the impairment of immunologic self-tolerance in GBS. Acute-phase AIDP and AMAN patients have been shown to exhibit reduced amount of Tregs. FOXP3 expression and the suppressive function of Tregs were found preserved in certain studies, suggesting that a reversible decrease of functionally intact Tregs can be responsible for the self-limited monophasic disease course [91]. More recent results revealed that not only the number of FOXP3+ Tregs is decreased, but their function is also defective. Furthermore, GBS patients have increased numbers of Th1, Th17, and Th22 cells, especially in the acute phase of the disease [92, 93]. The elevated Th22 cell count correlates with disease severity; however, it does not correlate with the subtype of the disease. GBS patients have higher levels of the pro-inflammatory molecules IL-17 and IL-22 [93].**

The therapeutic action of IVIg in GBS **is complex. It is partly attributed** to the reduction of the amount of pathological autoantibodies through *anti-idiotypes*, in a dose-dependent manner. Subsequently, no complement activation and hence complement-mediated cytotoxicity occur. **IVIg can prevent the binding of pathogenic antibodies, such as the anti-ganglioside antibodies, to the target antigen.** Other mechanisms, such saturation of FcRn, **alteration of FcR expression or an effect on the altered cytokine pathway might also be involved. In this respect, IVIg has been demonstrated to increase the amount of circulatory TGF $\beta$  in GBS patients. IVIg has also been shown to have an anti-complement effect; it decreases the serum levels of C1q and C4, and diminishes the complement activity [11, 94]. IVIg has also been evidenced to modify T cell response in GBS [94, 95]. As discussed above, a reduction of Tregs and an imbalance of the regulation of the different T cell subtypes occurs in GBS. IVIg therapy significantly increases**

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

the number of Tregs in GBS patients along with the improvement of the neurological signs [91]. Furthermore, IVIg induces a proliferation of pre-existing FOXP3+ Treg cells and improves their suppressive function; however, after four weeks, the amount of Tregs returns to the pre-treatment levels [92]. On the other hand, IVIg therapy reduces the number of Th1, Th17, and Th22 cells, as well as the production of effector molecules, such as IL-17, IL-22, IFN $\gamma$ , and GM-CSF [92, 93]. This results in a reciprocal regulation of Th1/Th17 and Treg, a process dependent on the up-regulation of the pro-inflammatory cytokine IL-10, capable of inhibiting Th17 cell function and stimulating Tregs. IVIg also interacts with DCs and consequently stimulates Tregs through different pathways, such as the induction of cyclooxygenase-2-dependent PGE2. In GBS patients, increased levels of PGE2 were observed following IVIg treatment [50]. IVIg may also neutralize inflammatory cytokines and can inhibit B cells, which effects might be of importance in the axonal forms of GBS [92].

#### 6.1.2. Treatment of GBS

PE has been used in the treatment of GBS since the '80s. On the other hand, steroids have been proven to be ineffective [79]. The list of clinical trials that examined IVIg for the treatment of GBS is provided in Table 5 [96-105].

### **6.2. Chronic inflammatory demyelinating polyneuropathy**

CIDP is a chronic, acquired, immune-mediated polyneuropathy, associated with a chronic progressive or relapsing-remitting course. CIDP is a rare disease, with a prevalence rate between 1 and 9 per 100,000 population, increasing with age [106].

#### 6.2.1. Clinical presentation

The classic form of CIDP has a symmetric presentation with the motor involvement being more severe than the sensory symptoms. Weakness affects both proximal and distal muscles. Furthermore, up to 20% of patients have cranial nerve and bulbar involvement as well. The sensory signs include pain, and impaired vibration and position sense, leading to an ataxic gait. Autonomic

1 involvement may occur in more severe cases [80]. ENG and nerve biopsy show signs of  
2 demyelination, but the indication for the latter is getting restricted to cases with an unclear  
3 diagnosis. CSF analysis reveals albuminocytologic dissociation. There are several diagnostic  
4 criteria for CIDP; relying on the clinical presentation, ENG results and CSF analysis, the most  
5 widely used one is the European Federation of Neurological Societies (EFNS) criteria [107]. CIDP  
6 variants differ from the classical form in terms of clinical presentation, pathomechanism, ENG  
7 alterations, and the response to therapy [108].

18  
19  
20 6.2.2. Pathomechanism and mechanism of action of IVIg in CIDP The pathomechanism of CIDP  
21 has not yet been fully elucidated. An autoimmune inflammation is presumed to be responsible for  
22 the demyelination of the nerve roots and nerve trunks. Although, it is not clear whether the  
23 inflammation is attributable to humoral or cellular immune mechanisms, they are presumed to  
24 act synergistically to cause damage to the peripheral nerves.

25  
26  
27  
28  
29  
30  
31 Demyelination, onion bulb formation, axonal degeneration, and perivascular/endoneurial  
32 macrophage and T cell infiltration can be detected in sural nerve biopsy specimens. Besides  
33 removing debris, macrophages play a role in the development of inflammation. An upregulation of  
34 MHC II molecules necessary for antigen presentation and that of the costimulatory molecules, B7-1  
35 and B7-2, occurs in macrophages and other inflammatory cells. Furthermore, a secretion of pro-  
36 inflammatory cytokines has also been evidenced [80]. All these result in the activation of T cells. A  
37 clonal expansion of CD8<sup>+</sup> cytotoxic T cells has been observed in sural nerve biopsy specimens;  
38 whereas, on the other hand, Tregs are reduced in number and are less effective [109, 110]. **In CIDP**  
39 **patients, the activation of cytotoxic CD8<sup>+</sup> T cells is more pronounced than that of the CD4<sup>+</sup>**  
40 **cells, suggesting an important role of CD8<sup>+</sup> cells in the pathomechanism of the disease [95].**

41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53 Nerve biopsies reveal the disruption of the blood-nerve barrier (BNB), a phenomenon  
54 considered to be a critical step in the development of inflammation. Activated T cells adhere to  
55 endothelial cells via adhesion molecules (such VCAM-1 and ELAM-1) that are upregulated due to  
56  
57  
58  
59  
60

1 the inflammatory process through the action of cytokines and chemokines. As a result, T cells cross  
2 the BNB and influence the permeability of molecules restricted in normal conditions, such as  
3 antibodies [80].  
4  
5  
6  
7

8 Immunoglobulins and complement deposits on Schwann cells can also be observed in  
9 biopsy specimens, as a proof of the involvement of humoral mechanisms. Although neither the  
10 presumed infectious trigger of the autoimmune response, nor the putative antigen on the Schwann  
11 cell or the myelin is known, the presence of anti-ganglioside antibodies as well as the beneficial  
12 effect of PE together support the essential role of antibody-mediated pathomechanism [15].  
13 Experimental evidence suggests that the target antigen might be located in the compact myelin  
14 (with potential targets including myelin proteins P0, P2, peripheral myelin protein 22 (PMP22), and  
15 connexin) or in the nodal, paranodal, or juxtaparanodal regions. Antibodies have been detected  
16 against the nodal cell adhesion molecules (CAMs) gliomedin and neurofascin-186 (NF186), as well  
17 as against the paranodal contactin-1/caspr-1 complexes bound to the glial neurofascin-155 (NF155)  
18 on the Schwann cells [90, 111, 112]. According to a study, 30% of patients have a serum IgG that  
19 can bind to the paranode or the node of Ranvier, and the disruption of nodal and paranodal region  
20 has also been detected in biopsy specimens [113].  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36

37 There are CIDP patients with a severe form of the disease who exhibit antibodies of the  
38 IgG4 subtype to NF155 [114]. IgG4 antibodies are considered to be anti-inflammatory due to their  
39 reduced affinity to complement and Fc receptors; however, they can become pathogenic through an  
40 antigen-blocking mechanism via blocking the functions of the target antigen [111]. Patients carrying  
41 IgG4 auto-antibodies against contactin-1 generally present with a disease form characterized by a  
42 subacute onset, a severe disease course, sensory ataxia, and are associated with a poor response to  
43 IVIg and a better outcome with corticosteroid therapy, suggesting a different underlying  
44 pathomechanism [115]. **A dysregulation of the inhibitory FcγRIIB receptor expression occurs  
45 in CIDP patients. In untreated patients, the expression levels of FcγRIIB on B cells are lower  
46 than in healthy controls, and its upregulation does not occur or cannot be maintained as the**  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1 cells develop from the naive state to memory cells. 43% of CIDP patients carry a rare  
2 **FcγRIIB promoter polymorphism that results in a reduced promoter activity; however, its**  
3  
4 **role in disease pathomechanism has not yet been fully elucidated [116].**  
5  
6  
7

8 As detailed above, IVIg therapy can theoretically interfere with several steps and  
9 mechanisms described in the above sections discussing the pathomechanism of CIDP. However, the  
10 symptomatic effect of IVIg lasts only for about 3 weeks in most of the CIDP cases, and repeated  
11 doses are needed at different time intervals for each patient. These dose-dependent effects suggest  
12 that IVIg might act through the action of anti-idiotypic antibodies, **but several other mechanisms**  
13 **of action have been implicated. Indeed, IVIg therapy regulates FcRs in CIDP, as it**  
14 **upregulates FcγRIIB expression on B cells and monocytes, resulting in an anti-inflammatory**  
15 **effect [116]. Another effect of IVIg is the reduction of activated T cells, a cell type considered**  
16 **to play an important role in the pathogenesis of the disease [95]. In addition, IVIg also targets**  
17 **B cell-activating factor (BAFF), a molecule released from DCs, monocytes, and granulocytes,**  
18 **and plays essential roles in B cell homeostasis, maturation, survival, and antibody production,**  
19 **and can also regulate T cells. BAFF plays a role in several autoimmune diseases, as its**  
20 **overexpression leads to the survival of autoreactive B cells and to auto-antibody production.**  
21 **In CIDP patients, the serum level of BAFF is elevated [117, 118]; furthermore, IVIg reduces**  
22 **BAFF expression and transcription, inhibits BAFF release in monocytes, and diminishes**  
23 **elevated BAFF levels in the serum of CIDP patients. Its action on BAFF is implicated among**  
24 **the FcγR-independent mechanisms of action of IVIg [117]. IVIg preparations contain**  
25 **antibodies against BAFF, which can be responsible for the short-term decrease of BAFF levels**  
26 **detected after IVIg therapy. On the basis of this, BAFF levels could be used as biomarkers of**  
27 **therapeutic response [118].**  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54

### 55 6.2.3. The treatment of CIDP

56 The therapy of CIDP includes corticosteroids, PE, IVIg, and immunosuppressive agents,  
57  
58  
59  
60

1 according to the EFNS guideline [107]. It is recommended to start with steroids or IVIg as first-line  
2 therapy, and switch to other therapeutic options in case of insufficient clinical response. Although  
3 steroids are considered as first-line therapy for CIDP, their efficacy has only been investigated in a  
4 single randomized-controlled trial (RCT) [119]. PE was shown to be effective in two RCTs in about  
5 33-66% of patients; however, side effects related to the therapy itself or the maintenance of the  
6 venous access were frequently reported [120].  
7  
8  
9  
10  
11  
12  
13

14  
15 Several clinical trials proved the efficacy of IVIg for the treatment of CIDP. RCTs found  
16 comparable short-term efficacy of IVIg as compared to oral steroids [121] and to PE [122]. IVIg  
17 proved more efficacious as compared to placebo in earlier RCTs [123-126]. A meta-analysis  
18 comparing the effect of IVIg to placebo, corticosteroid therapy, and PE, concluded that the efficacy  
19 in terms of muscle strength and the reduction of disability is short-term, lasting only for 2-3 weeks  
20 [127].  
21  
22  
23  
24  
25  
26  
27

28 The ICE trial was an RCT that compared the long-term efficacy and safety of IVIg-caprylate  
29 to placebo in a total of 117 patients with CIDP. It concluded that the overall short-term  
30 improvement achieved with IVIg, as regards the improvement in the Inflammatory Neuropathy  
31 Cause and Treatment (INCAT) score and other efficacy measures, was significantly better as  
32 compared to placebo. The extension study revealed the long-term efficacy of IVIg-caprylate given  
33 every 3 weeks as a maintenance therapy for patients with CIDP. On the other hand, therapy  
34 withdrawal increased the risk of a relapse. The study also showed that the loading dose of 2 g/kg  
35 and the maintenance dose of 1 g/kg can be given safely in short time frames of 2 and 1 day,  
36 respectively, that might also be a cost-saving approach [128].  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47

48 The PRIMA study investigated efficacy and safety of Privigen in patients with CIDP in a  
49 prospective, single-arm, open-label Phase III trial. Patients received the standard induction dose of  
50 2 g/kg and maintenance doses of 1 g/kg every 3 weeks. The responder rate was above 60%, and  
51 improvements could be observed in the INCAT score, the grip strength, and the Medical Research  
52 Council (MRC) sum score. The study also proved that patients who were non-responders after 6  
53  
54  
55  
56  
57  
58  
59  
60

1 weeks may respond later to IVIg therapy, and a longer period should be considered in order to  
2  
3 declare a person non-responder to IVIg. Adverse events were mild to moderate, but cases of  
4  
5 hemolysis occurred [129].  
6  
7

8 In 2013, an extensive meta-analysis evaluated the RCTs assessing the efficacy of IVIg for  
9  
10 the treatment of CIDP. In this analysis, IVIg lead to a significant improvement in disability scores  
11  
12 within 6 weeks of treatment initiation. In order to compare the results of the trials, the different  
13  
14 disability scores applied were transformed into the modified Rankin score, and the overall result  
15  
16 demonstrated an improvement in the IVIg-treated patients. Long-term benefit was revealed in only  
17  
18 one trial included in the meta-analysis, which has already been discussed in detail above [128].  
19  
20 There was no significant difference between IVIg and PE, and between prednisolone and IVIg in  
21  
22 terms of therapeutic benefit in CIDP [62].  
23  
24

25 A retrospective analysis of the effect of immune therapies in patients with CIDP carried out  
26  
27 in Italy concluded that 69% of patients responded to the first-line therapy (corticosteroid therapy or  
28  
29 IVIg), whereas 81% responded after switching the therapy in the case of a non-responder state. This  
30  
31 study demonstrated that the lack of response to one therapy does not exclude a potential response to  
32  
33 another immune therapy. The efficacy of IVIg was slightly higher as compared to corticosteroid  
34  
35 therapy, whereas the side effect profile was more favorable as compared to PE [130].  
36  
37

38 A study conducted on 45 patients compared the efficacy and tolerability of IVIg  
39  
40 (0.5 g/kg/day for 4 consecutive days) compared to intravenous methylprednisolone (0.5 g/day for 4  
41  
42 consecutive days) given monthly during a 6-month period. The study concluded that the number of  
43  
44 patients having discontinued the therapy was higher in the methylprednisolone-treated group,  
45  
46 though the occurrence of side effects did not differ in the two groups. The efficacy of IVIg was  
47  
48 superior; however, the number of patients who worsened and required further therapy was higher in  
49  
50 the IVIg group [131].  
51  
52  
53  
54  
55  
56

### 57 **6.3. Disorders mimicking CIDP – multifocal motor neuropathy**

58  
59  
60



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

There are disorders mimicking CIDP but considered as separate entities due to a different clinical presentation, specific pathophysiologic features, and a different response to therapy as compared to the classic form. Due to length limitations, only multifocal motor neuropathy (MMN) is described in detail in this paper, although other forms also respond to IVIg therapy [108] (Table 4).

MMN is a chronic immune-mediated neuropathy with an asymmetric presentation mostly involving distal upper limbs, without sensory involvement. ENG examination reveals multifocal motor conduction blocks, with preserved sensory conduction [131]. Up to 60% of patients have anti-GM1 IgM antibodies, the presence of which might correlate with disease severity [132, 133]. Over 60% of patients have antibodies against gliomedin or NF186, and some 10% of the anti-GM1-negative patients are positive for anti-NF186 antibodies [134]. Complement activation and an autoantibody-induced complement attack on ganglioside-rich nerve structures are presumed to underlie the pathological changes seen in the peripheral nerves [15]. MMN responds to IVIg therapy; however, it does not respond to PE or corticosteroid treatment [135, 136]. Axonal excitability improves after IVIg infusions, an effect waning in time, however. IVIg is presumed to act in MMN predominantly via complement inhibition [137]. Another possibility is that IVIg exerts its effect through a competitive mechanism by anti-idiotypic antibodies. The T<sub>1/2</sub> of IgM is short, as it is not recycled by the FcRn, and, therefore, IVIg presumably does not act via an increased catabolism of the pathological antibody. The effect of IVIg lasts for a few weeks, and maintenance therapy is needed for MMN patients.

## 7. Conclusions

IVIg has a complex but not fully elucidated mechanism of action. The beneficial effect last beyond the half-life, suggesting that it is not simply due to an enhanced passive clearance of or an interference with pathogenic antibodies, but to a complex mechanism involving complement inhibition, interference with the cytokine network, modulation of the expression of Fc receptors, as

1 well as an effect on DCs, T cells, and B cells. Though neither the specific mechanism of action of  
2  
3  
4 IVIg in autoimmune neuropathies nor the pathomechanism of all the affected diseases is fully  
5  
6 understood, clinical trials have proven the efficacy of IVIg in these conditions. IVIg is generally  
7  
8 well tolerated, being associated with only few severe side effects.  
9

## 10 11 12 13 **8. Expert opinion**

14  
15 IVIg therapy has a proven efficacy in the treatment of several autoimmune diseases;  
16  
17 however, it is a costly and non-specific therapy with a limited access worldwide. IVIg treatment  
18  
19 meets several challenges.  
20

21  
22 The relationship between pharmacokinetics and pharmacodynamics of IVIg in  
23  
24 neuromuscular disorders is complex, and is presumed to depend on the mechanisms involved in the  
25  
26 disease pathomechanism. This relationship is even more difficult to understand in light of the fact  
27  
28 that neither the exact pathomechanism of some of the neurological diseases in which IVIg therapy  
29  
30 has been proven to be effective, nor the mechanism of IVIg is fully understood. A rapid onset and  
31  
32 the short-lasting, dose-dependent effect are presumed to be the consequence of the competition of  
33  
34 the high concentrations of IVIg with the pathological antibody for the binding sites, whereas the  
35  
36 late, longer-lasting, and less dose-dependent effect is presumed to be the result of more complex  
37  
38 cellular (involving lymphocytes and APCs) and molecular interactions induced by IVIg. In cases  
39  
40 where a rapid short-duration response is achieved, most probably due to antibody competition, it is  
41  
42 likely that antibodies play the key role in the pathomechanism of the target tissue dysfunction (*i.e.*,  
43  
44 nerve dysfunction, or neuromuscular junction dysfunction). Further research is necessary to better  
45  
46 understand the mechanisms of action of IVIg and the pathomechanism of immune diseases.  
47  
48  
49

50  
51 Immune-mediated polyneuropathies are a heterogeneous group of disorders of the peripheral  
52  
53 nervous system. Despite the considerable progress in the fields of supportive therapy and  
54  
55 immunotherapy, GBS is still a life-threatening disease, which can result in permanent disability in  
56  
57 as many as 20% of patients. The chronic forms are difficult to diagnose, and, especially in case of a  
58  
59  
60

1  
2 delay in the initiation of the therapy, a severe disability and an impairment of the quality of life can  
3  
4 ensue. There is still much to do in order to improve the therapy for immune-mediated  
5  
6 polyneuropathies. More easier to use diagnostic criteria for daily clinical practice even for non-  
7  
8 neurologists might raise the clinical diagnostic yield. The continuous improvement of the  
9  
10 prognostic factors in acute polyneuropathies is essential to aid the selection of patients that are at  
11  
12 high risk of developing respiratory insufficiency and severe complications. In chronic  
13  
14 polyneuropathies, the response to a therapy is sometimes difficult to assess, especially in case of a  
15  
16 long-lasting disease with a severe disability at baseline. Future advancements in clinical outcome  
17  
18 measures may improve the choice of more individualized therapy. Another challenge is the paucity  
19  
20 of specific guidelines on how to tailor IVIg maintenance therapy, and when and how to start  
21  
22 tapering the doses in order to offer an effective but also cost-effective therapy. What we see in  
23  
24 clinical practice is that patients need an individualized therapy. Some patients experience a wearing  
25  
26 off of the effect even before that could be expected on the basis of the T1/2 of IVIg, whereas, in  
27  
28 other cases, the effect lasts longer and the patient requires less frequent maintenance infusions. On  
29  
30 the basis of these, in a chronic disease such as CIDP, clinical studies are warranted to aid the  
31  
32 tailoring of long-term therapy, with special focus on the delineation of the terms of dose reduction  
33  
34 and interruption of IVIg treatment. More accurate clinical scores would be of use for the assessment  
35  
36 of the therapeutic effect not only in clinical trials but also in the clinical setting. Biological markers  
37  
38 of the disease might help to predict the clinical outcome and to identify patients for whom a good or  
39  
40 longer-lasting response to IVIg therapy is expected. The revelation of possible correlations between  
41  
42 therapy-related serum IgG levels and the observed clinical response might be of help in optimizing  
43  
44 the doses and may reduce the expenses. Another approach could be to aim at maintaining a steady  
45  
46 serum IgG level to compete with the pathological autoantibody.  
47  
48  
49  
50  
51

52  
53 The availability of IVIg is limited, the expenses are high, and, in several diseases, a chronic  
54  
55 therapy is necessary to maintain the immunomodulatory effect. The better understanding of the  
56  
57 mechanism of action of IVIg could open the possibility of the development of disease-specific,  
58  
59  
60

1 targeted immune therapies, and non-plasma-derived medicines. Tregs can provide immunological  
2 tolerance in autoimmune diseases; therefore, therapies targeting Treg expansion and activation are  
3 of interest.  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For Peer Review Only





Figure 1. Immunoglobulin G molecule, schematic representation

Figure 2. Mechanism of action of IVIg



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47

<p><u>Neurological disorders</u></p> <ul style="list-style-type: none"> <li>• <b>CIDP</b></li> <li>• <b>Guillain-Barré syndrome (GBS)</b></li> <li>• <b>Multifocal motor neuropathy (MMN)</b></li> <li>• Paraproteinemic (IgM) neuropathy</li> <li>• Dermatomyositis or polymyositis</li> <li>• Myasthenic exacerbation</li> <li>• Lambert-Eaton myasthenic syndrome (LEMS)</li> <li>• Multiple sclerosis, relapsing-remitting (RRMS)</li> <li>• Neuromyelitis optica (NMO)</li> <li>• Stiff-person syndrome</li> <li>• Lennox-Gastaut syndrome</li> <li>• Rasmussen syndrome</li> </ul> <p><u>Infectious diseases</u></p> <ul style="list-style-type: none"> <li>• <b>Pediatric HIV type 1 infection</b></li> <li>• Lymphoproliferative disease, treatment of bacterial infections</li> <li>• CMV-pneumonitis in solid organ transplants</li> <li>• Enteroviral meningoencephalitis</li> <li>• Rotaviral enterocolitis</li> <li>• Staphylococcal toxic shock</li> <li>• Thrombocytopenia, secondary to HCV, HIV</li> </ul> <p><u>Other</u></p> <ul style="list-style-type: none"> <li>• Asthma (steroid-dependent)</li> <li>• Autoimmune uveitis</li> <li>• Graves' ophthalmopathy</li> <li>• Diabetes mellitus</li> <li>• Rheumatoid arthritis, severe form</li> <li>• Systemic lupus erythematosus</li> <li>• Systemic vasculitides</li> <li>• Recurrent pregnancy loss.</li> </ul>	<p><u>Hematological disorders</u></p> <ul style="list-style-type: none"> <li>• <b>Allogeneic bone marrow transplantation</b></li> <li>• <b>Hematopoietic stem cell transplantation in patients above 20 years</b></li> <li>• <b>Chronic lymphocytic leukemia</b></li> <li>• <b>Common variable immunodeficiency (CVID)</b></li> <li>• <b>Kidney transplantation with a high antibody recipient or with an ABO incompatible donor</b></li> <li>• <b>Primary immunodeficiency disorders associated with defects in humoral immunity.</b></li> <li>• <b>Idiopathic thrombocytopenic purpura (ITP)</b></li> <li>• <b>Kawasaki disease</b></li> <li>• Aplastic anemia</li> <li>• Autoimmune hemolytic anemia</li> <li>• Acquired factor VIII inhibitors</li> <li>• Acquired von Willebrand disease</li> <li>• Immune-mediated neutropenia</li> <li>• Refractoriness to platelet transfusion</li> <li>• Thrombotic thrombocytopenic purpura / hemolytic-uremic syndrome</li> <li>• Post-transfusion purpura</li> <li>• Fetomaternal alloimmune thrombocytopenia</li> <li>• Renal transplantation, prevention of acute humoral rejection</li> <li>• Monoclonal gammopathy</li> </ul> <p><u>Dermatologic diseases</u></p> <ul style="list-style-type: none"> <li>• Toxic epidermal necrolysis and Stevens-Johnson syndrome</li> <li>• Delayed pressure urticaria</li> <li>• Autoimmune bullous diseases</li> </ul>
--	--

Table 1. Conditions in which IVIg can be used. On-label indications are in bold letters.

<p>Anti-idiotypic antibodies against</p> <ul style="list-style-type: none"> <li>• anti-neutrophil cytoplasmic antibody</li> <li>• anti-DNA</li> <li>• anti-acetylcholine receptor</li> <li>• anti-factor VIII</li> <li>• anti-thyreoglobulin</li> <li>• anti-GAD</li> <li>• anti-ganglioside</li> <li>• anti-HLA</li> </ul>
<p><u>Antibodies against receptors, such as:</u></p> <ul style="list-style-type: none"> <li>• CD5</li> <li>• CD95 (FAS)</li> <li>• CD95 ligand (FASL)</li> <li>• sialic acid-binding immunoglobulin-like lectin 8 (SIGLEC8) on eosinophils</li> <li>• SIGLEC9 on neutrophils</li> <li>• T cell receptors (TCRs)</li> </ul>
<p><u>Antibodies against</u></p> <ul style="list-style-type: none"> <li>• blood group antigens</li> <li>• <b>cytokines</b></li> <li>• B cell-activating factor (BAFF)</li> <li>• a proliferation-inducing ligand (APRIL)</li> <li>• adhesion molecules involved in leucocyte trafficking</li> <li>• anaphylatoxins (C3a, C5a)</li> </ul>

Table 2. Antibodies present in IVIg preparations with potential importance in the immunomodulatory effect.



	<i>Mild</i>	<i>Moderate</i>	<i>Severe</i>
<i>Immediate</i>	local pain, swelling headache myalgia, arthralgia nausea, vomiting hypotension, hypertension tachycardia fever, chills fatigue	-	anaphylactic reactions
<i>Delayed</i>	neutropenia hyponatremia	headache aseptic meningitis anemia eczema	renal failure nephrosis tubular necrosis thrombosis colitis <b>PRES</b>
<i>Late</i>	-	interference with vaccines	infectious diseases

Table 3. IVIg-related adverse events. See text for references

<i>Form</i>	<i>Nerve conduction</i>	<i>Antibodies against</i>
<b>Acute</b>		
GBS (AIDP)	demyelinating	GM2, GQ1b, NF186
Miller Fisher syndrome	demyelinating	GQ1b, GT1a
acute motor axonal (AMAN)	axonal	GM1a, GM1b, GD1a, GalNAc-GD1a, NF186
acute motor and sensory axonal (AMSAN)	axonal	GM1, GD1a
pharyngeal-cervical-brachial variant	demyelinating	GQ1a
<b>Chronic</b>		
CIDP	demyelinating	Presumed: gliomedin, NF186, paranodal contactin-1/caspr-1 complex bound to glial NF155, NF155
pure motor CIDP	demyelinating	not known
sensory CIDP	demyelinating	not known
distal acquired demyelinating sensory (DADS)	demyelinating	MAG
multifocal acquired demyelinating sensory and motor (MADSAM) (Lewis Sumner)	demyelinating	not known
axonal variants	axonal	not known
focal CIDP	demyelinating	not known
<b>CIDP mimics</b>		
Multifocal motor neuropathy with conduction block (MMN)	demyelinating	GM1
Paraprotein associated CIDP	demyelinating/axonal	MAG, (IgM), not known (IgG, IgA)
Chronic ataxic neuropathy with ophthalmoparesis, M protein, cold agglutinins and disialosyl ganglioside antibodies (CANOMAD)	demyelinating	disialosyl ganglioside
Polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy and skin changes (POEMS)	demyelinating/axonal	not known (IgG, IgA paraprotein)

Table 4. Classification of immune-mediated polyneuropathies.

<b>Comparison of IVIg vs supportive treatment or dexamethasone</b>							
<i>Type</i>	<i>Number of patients (age)</i>	<i>Dose of IVIg</i>	<i>Comparator</i>	<i>Endpoint</i>	<i>Recovery time (d)</i>	<i>Result</i>	<i>Ref.</i>
Quasi-randomized, single-center, parallel-group	9 vs 9 (< 18 y)	1.0 g/kg for 2 days	supportive treatment	days for unaided walking	15 vs 24.5	IVIg was superior	<b>99</b>
Randomized, single-center, parallel-group	20 vs 16 (< 18 y)	0.2-0.3 g/kg for 5-6 days	dexamethasone (4-5 mg for 5-6 days)	days to improve on disability scale	17.1 vs 24.8 (IVIg vs dexamethasone)	IVIg was superior	<b>104</b>
Randomized, multicenter, parallel-group	14 vs 7 (< 18 y)	1.0 g/kg for 2 days	no treatment	days to improve on disability scale	8 vs 32	IVIg was superior	<b>100</b>
<b>Comparison of IVIG vs PE</b>							
<i>Type</i>	<i>Number of patients</i>	<i>Dose of IVIg</i>	<i>Dose of PE</i>	<i>Follow-up</i>	<i>Endpoint</i>	<i>Result</i>	<i>Ref</i>
Randomized, national, multicenter, parallel-group	150 adults and children	0.4 g/kg for 5 days	200-250 ml/kg	4 weeks	median days to improve one grade point: 27 vs 41	IVIg was superior	<b>103</b>
Randomized, single-center, parallel-group	50 adults	0.5 g/kg for 4 days	200-250 ml/kg	no data	multiple outcome measures	NS	<b>96</b>
Randomized, international, multicenter, parallel-group	379	0.4 g/kg for 5 days	250 ml/kg	4 weeks	improvement on a disability scale	NS	<b>102</b>
Randomized, multicenter, parallel-group	23 vs 24	0.4 g/kg for 5 days	200-250 ml/kg	4 weeks	improvement on a disability scale	NS	<b>101</b>
Randomized, multicenter, parallel-group	25 vs 26	0.4 g/kg for 5 days	200-250 ml/kg	4 weeks	improvement on a disability scale	NS	<b>97</b>
Randomized, single-center, parallel group, ICU	20 vs 21	0.4 g/kg for 5 days	200-250 ml/kg	4 weeks	median days in ICU: 13 vs 11	NS	<b>98</b>

Table 5. Main characteristics of clinical trails with IVIg

**Conflict of interest**

The authors declare that they have no conflict of interest and have received no payment in preparation of their manuscript.

**Acknowledgements**

We acknowledge Mr. Levente Szalárdy, MD for the linguistic correction of the manuscript.

For Peer Review Only

## References

[1] Bruton OC. Agammaglobulinemia. *Pediatrics* 1952; 9(6):722–8

[2] Imbach P, Barandun S, Baumgartner C, et al. High-dose intravenous gammaglobulin therapy of refractory, in particular idiopathic thrombocytopenia in childhood. *Helv Paediatr Acta* 1981;36(1):81–6

[3] US Food and Drug Administration. Drugs. Available at <http://www.fda.gov/Drugs/default.htm>. [Last accessed 19 April 2016]

[4] Scheinfeld NS. Intravenous immunoglobulin. Available at: <http://emedicine.medscape.com/article/210367-overview#a2> [Last updated 03 February 2016]

[5] Buehler AM, Flato UP, Ferri CP et al. Is there evidence for recommending specific intravenous immunoglobulin formulations? A systematic review of head-to-head randomized controlled trials. *Europ J Pharmacol* 2015;747:96-104

[6] Gelfand EW. Intravenous immune globulin in autoimmune inflammatory disease. *N Engl J Med* 2012;367:2015-25

[7] Ballow M. The IgG molecule as a biological immune response modifier: mechanism of action of intravenous immune serum globulin in autoimmune and inflammatory disorders. *J Allergy Clin Immunol* 2011;127(2):315-23

[8]\*\* Kaveri SV, Lecerf M, Saha C et al. Intravenous immunoglobulin and immune response. *Clin Exp Immunol* 2014;178: 94–96

\*\*This paper and paper [16] give a good insight into the mechanism of action of IVIg

[9] Mitrevski M, Marrapodi R, Camponeschi A, et al. Immunomodulatory effects of intravenous immunoglobulin-assembling a jigsaw puzzle. *Internat Trends Immunol* 2014. Available at: <http://researchpub.org/journal/iti/number/vol2-no2/vol2-no2-1.pdf>

[10] **Silvergleid AJ, Ballow M. Overview of intravenous immune globulin (IVIg) therapy. Available at: <http://www.uptodate.com/contents/overview-of-intravenous-immune-globulin->**

1  
2 **ivig-therapy [Last updated 23 February 2016]**  
3  
4

5 **[11] Bienvenu B, Cozon G, Hoarau C et al. Does the route of immunoglobulin replacement**  
6 **therapy impact quality of life and satisfaction in patients with primary immunodeficiency?**  
7 **Insight from the French cohort „Visages”. Orphanet J Rare Dis 2016; published online 22**  
8 **June 2016, doi: 10.1186/s13023-016-0452-9**  
9

10  
11  
12  
13 **[12] Rajabally YA. Subcutaneous immunoglobulin therapy for inflammatory neuropathy:**  
14 **current evidence base and future prospects. J Neurol Neurosurg Psychiatry 2014;85:631-37**  
15  
16

17  
18 **[13] American Academy for Allergy Asthma and Immunology. Eight guiding principles for**  
19 **effective use of IVIG for patients with primary immunodeficiency. Available at:**  
20 **[https://www.aaaai.org/Aaaai/media/MediaLibrary/PDF%20Documents/Practice%20Resource](https://www.aaaai.org/Aaaai/media/MediaLibrary/PDF%20Documents/Practice%20Resources/IVIG-guiding-principles.pdf)**  
21 **s/IVIG-guiding-principles.pdf [Last accessed 25 June 2016]**  
22  
23  
24

25  
26  
27 [14] Kuitwaard K, van Doorn PA, Vermeulen M. Serum IgG levels in IV immunoglobulin treated  
28 chronic inflammatory demyelinating polyneuropathy. J Neurol Neurosurg Psychiatry 2013;84:859–  
29 61  
30  
31

32  
33 [15]\*\* Berger M, Mc Callus DE, Shin-Yi C. Rapid and reversible responses to IVIG in autoimmune  
34 neuromuscular diseases suggest mechanisms of action involving competition with functionally  
35 important autoantibodies. J Periph Nervous System 2013;18:275–96  
36  
37

38 \*\*This paper is a thorough review of the uses of IVIg in neurological disorders  
39  
40

41 [16]\*\* Schwab I, Nimmerjahn F. Intravenous immunoglobulin therapy: how does IgG modulate the  
42 immune system? Nat Rev Immunol 2013;13(3):176-89  
43  
44

45 \*\*This paper and paper [8] give a good insight into the mechanism of action of IVIg  
46  
47

48 [17] Hansen RJ, Balthasar JP. Effects of intravenous immunoglobulin on platelet count and  
49 antiplatelet antibody disposition in a rat model of immune thrombocytopenia. Blood  
50 2002;100:2087–93  
51  
52

53  
54  
55 [18] Li N. Complete FcRn dependence for intravenous Ig therapy in autoimmune skin blistering  
56 diseases. J Clin Invest 2005;115:3440–50  
57  
58  
59  
60

1  
2 [19] Nimmerjahn F, Ravetch JV. FcγRs in health and disease. *Curr Top Microbiol Immunol*  
3 2011;350:105-25  
4

5  
6  
7 **[20] Tankersley DL. Dimer formation in immunoglobulin preparations and speculations on**  
8 **the mechanism of action of intravenous immune globulin in autoimmune diseases. *Immunol***  
9 **Rev 1994;139:159-72**  
10

11  
12  
13 **[21] Ritter C, Bobylev I, Lehmann HC. Chronic inflammatory demyelinating polyneuropathy**  
14 **(CIDP): change of serum IgG dimer levels during treatment with intravenous**  
15 **immunoglobulins. *J Neuroinflammation*: published online 14 August 2015, doi:**  
16 **10.1186/s12974-015-0361-1**  
17  
18  
19

20  
21  
22 **[22] Schaub A, Wymann S, Heller M, Ghielmetti M, Belezny Z, Stadler BM, Bolli R,**  
23 **Miescher S. Self-reactivity in the dimeric intravenous immunoglobulin fraction. *Ann N Y***  
24 **Acad Sci 2007;1110:681-93**  
25  
26

27  
28 [23] Washburn N, Schwab I, Ortiz D, et al. Controlled tetra-Fc sialylation of IVIg results in a drug  
29 candidate with consistent enhanced anti-inflammatory activity. *Proc Natl Acad Sci USA*  
30 2015;112(11):1297–306  
31  
32

33  
34  
35 [24] Sondermann P, Pincetic A, Maamary J, et al. General mechanism for modulating  
36 immunoglobulin effector function. *Proc Natl Acad Sci USA* 2013;110(24):9868–72  
37  
38

39  
40 [25] Chen XX, Chen YQ, Ye S. Measuring decreased serum IgG sialylation: a novel clinical  
41 biomarker of lupus. *Lupus* 2015;24(9):948–54  
42  
43

44  
45 [26]\* Kaufman G, Massoud A, Dembele M, et al. Induction of regulatory T cells by intravenous  
46 immunoglobulin: a bridge between adaptive and innate immunity. *Front Immunol* 2015: published  
47 online 11 September 2015, doi: 10.3389/fimmu.2015.00469  
48  
49

50 \*This paper presents the effect of IVIg on regulatory T cells  
51

52  
53 [27] Anthony RM, Wermeling F, Karlsson MC, et al. Identification of a receptor required for the  
54 anti-inflammatory activity of IVIG. *Proc Natl Acad Sci USA* 2008;105(50):19571–78  
55  
56

57  
58 [28] Anthony RM, Wermeling F, Ravetch JV. Novel roles for the IgG Fc glycan. *Ann N Y Acad Sci*  
59  
60

1  
2 2012;1253:170–80  
3

4  
5 [29] Pincetic A, Bournazos S, DiLillo DJ, et al. Type I and type II Fc receptors regulate innate and  
6 adaptive immunity. *Nat Immunol* 2014;15(8):707–16  
7

8  
9  
10 **[30] Campbell IK, Miescher S, Branch DR et al. Therapeutic effect of IVIG on inflammatory**  
11 **arthritis in mice is dependent on the Fc portion and independent of sialylation of basophils. *J***  
12 ***Immunol* 2014;192:5031-8**  
13

14  
15  
16  
17 **[31] Sharma M, Schoindre Y, Hegde P et al. Intravenous immunoglobulin-induced IL-33 is**  
18 **insufficient to mediate basophil expansion in autoimmune patients. *Sci Reports* 2014:**  
19 **published online 11 July 2014, doi: f10.1038/srep05672**  
20  
21

22  
23 **[32] Nagelkerke SQ, Dekkers G, Kustiawan I et al. Inhibition of FcγRIIB in human**  
24 **macrophages. *Blood* 2014;124:3709-18**  
25  
26

27  
28 **[33] Othy S, Topcu S, Saha C et al. Sialylation may be dispensable for reciprocal modulation**  
29 **of helper T cells by intravenous immunoglobulin. *Eur J Immunol* 2014;44:2059-63**  
30  
31

32  
33 **[34] Issekutz AC, Rowter D, Miescher S et al. Intravenous IgG (IVIG) and subcutaneous IgG**  
34 **(SCIG) preparations have comparable inhibitory effect on IgG sialylation, monocytes or B**  
35 **cells. *Clinical Immunol* 2015;160:123-32**  
36  
37

38  
39  
40 [35] Kuitwaard K, de Gelder J, Tio-Gillen AP, et al. Pharmacokinetics of intravenous  
41 immunoglobulin and outcome in Guillain-Barre syndrome. *Ann Neurol* 2009;66:597–603  
42

43  
44  
45 [36] Hartung HP. Advances in the understanding of the mechanism of action of IVIg. *J Neurol*  
46 2008;255:3-6  
47

48  
49  
50 [37] Basta M, Van Goor F, Luccioli S, et al. F(ab)'2-mediated neutralization of C3a and C5a  
51 anaphylatoxins: a novel effector function of immunoglobulins. *Nat Med* 2003;9:431–38  
52

53  
54  
55 [38] Jang EJ, Nahm DH, Jang YJ. Mouse monoclonal autoantibodies penetrate mouse macrophage  
56 cells and stimulate NF-kappaB activation and TNF-alpha release. *Immunol Lett* 2009;124:70–76  
57  
58  
59  
60



1  
2 [39] Sali AD, Karakasiliotis I, Evangelidou M, et al. Immunological evidence and regulatory  
3 potential for cell-penetrating antibodies in intravenous immunoglobulin. *Clinical Transl Immunol*  
4 2015: published online 2 October 2015, doi:10.1038/cti.2015.18  
5  
6

7  
8 [40] Schwab I, Mihai S, Seeling M, et al. Broad requirement for terminal sialic acid residues and  
9 FcγRIIB for the preventive and therapeutic activity of intravenous immunoglobulins in vivo.  
10 *Eur J Immunol* 2014;44(5):1444–53  
11  
12

13  
14 [41] Zou T, Caton AJ, Koretzky GA, et al. Dendritic cells induce regulatory T cell proliferation  
15 through antigen-dependent and -independent interactions. *J Immunol* 2010;185(5):2790–9  
16  
17

18  
19 [42] Bayry J, Mouthon L, Kaveri SV. Intravenous immunoglobulin expands regulatory T cells in  
20 autoimmune rheumatic disease. *J Rheumatol* 2012;39:450–1  
21  
22

23  
24 [43] Massoud AH, Yona M, Xue D, et al. Dendritic cell immunoreceptor: a novel receptor for  
25 intravenous immunoglobulin mediates induction of regulatory T cells. *J Allergy Clin Immunol*  
26 2014;133:853–63  
27  
28

29  
30 [44] Trinath J, Hegde P, Sharma M, et al. Intravenous immunoglobulin expands regulatory T cells  
31 via induction of cyclooxygenase-2- dependent prostaglandin E2 in human dendritic cells. *Blood*  
32 2013;122:1419–27  
33  
34

35  
36 [45] Massoud AH, Guay J, Shalaby KH, et al. Intravenous immunoglobulin attenuates airway  
37 inflammation through induction of forkhead box protein 3-positive regulatory T cells. *J Allergy Clin*  
38 *Immunol* 2012;129(6):1656–65  
39  
40

41  
42 [46] Tang Q, Bluestone JA. The Foxp3+ regulatory T cell: a jack of all trades, master of regulation.  
43 *Nat Immunol* 2008;9(3):239–44  
44  
45

46  
47 [47] Ephrem A, Chamat S, Miquel C, et al. Expansion of CD4+CD25+ regulatory T cells by  
48 intravenous immunoglobulin: a critical factor in controlling experimental auto-immune  
49 encephalomyelitis. *Blood* 2008;111(2):715–22  
50  
51

52  
53 [48] Tha-In T, Metselaar HJ, Bushell AR, et al. Intravenous immunoglobulins promote skin  
54 allograft acceptance by triggering functional activation of CD4+Foxp3+ T cells. *Transplantation*  
55  
56

1  
2 2010;89(12):1446–55  
3  
4

5 [49] Cousens LP, Najafian N, Mingozi F, et al. In vitro and in vivo studies of IgG-derived Treg  
6 epitopes (Tregitopes): a promising new tool for tolerance induction and treatment of autoimmunity.  
7 J Clin Immunol 2013;33(Suppl 1):43–9  
8  
9

10  
11 **[50] Maddur MS, Trinath J, Rabin M et al. Intravenous immunoglobulin-mediated expansion**  
12 **of regulatory T cells in autoimmune patients is associated with increased prostaglandin E2**  
13 **levels in the circulation. Cell Mol Immunol 2015;12:650-2**  
14  
15

16  
17  
18 [51] Ballow M. Mechanisms of immune regulation by IVIG. Curr Opin Allergy Clin Immunol  
19 2014;14:509-15  
20  
21

22  
23 [52] Vani J, Elluru S, Negi VS, et al. Role of natural antibodies in immune homeostasis: IVIg  
24 perspective. Autoimmunity Rev 2008;7:440–44  
25  
26

27  
28 [53] Ramakrishna C, Newo AN, Shen YW, et al. Passively administered pooled human  
29 immunoglobulins exert IL-10 dependent anti-inflammatory effects that protect against fatal HSV  
30 encephalitis. PLoS Pathog 2011: published online 2 June 2011, doi:10.1371/journal.ppat.1002071  
31  
32

33  
34 [54] Nimmerjahn F, Ravetch JV. Anti-inflammatory actions of intravenous immunoglobulin.  
35 Annu Rev Immunol 2008;26:513–33  
36  
37

38  
39 [55] Altnauer F, von Gunten S, Spath P, et al. Concurrent presence of agonistic and antagonistic  
40 anti-CD95 autoantibodies in intravenous Ig preparations. J Allergy Clin Immunol  
41 2003;112(6):1185–90  
42  
43

44  
45 [56] Siberil S, Elluru SR, Negi VS, et al. Intravenous immunoglobulin in autoimmune and  
46 inflammatory diseases. More than mere transfer of antibodies. Transf Apher Science 2007;37:103-7  
47  
48

49 [57]\* Stiehm RE. Adverse effects of human immunoglobulin therapy. Transf Med Rev 2013;27:171-  
50 8  
51  
52

53  
54 \* This article gives an overview of the side effects of IVIg  
55  
56

57  
58 [58] Bonilla FA. Intravenous immunoglobulin: adverse reactions and management. J Allergy Clin  
59  
60

1  
2 Immunol 2008;122:1238–9.  
3  
4

5 [59] Donofrio PD, Brill V, Dalakas MC, et al. Safety and tolerability of immune globulin  
6 intravenous in chronic inflammatory demyelinating polyradiculoneuropathy. Arch Neurol  
7 2010;67:1082–8.  
8  
9

10  
11 [60] Dantal, J. Intravenous immunoglobulins: in-depth review of excipients and acute kidney injury  
12 risk. Am.J.Nephrol 2013;38:275–84  
13  
14

15  
16  
17 **[61] Martin TD. Safety and tolerability of intravenous immunoglobulins. In: Saud G editor.**  
18 **Treatment of neurological disorders with intravenous immunoglobulins. London. Martin**  
19 **Dunitz, 2000:181-91**  
20  
21

22  
23 [62]\*\* Eftimov F, Winer JB, Vermeulen M, et al. Intravenous immunoglobulin for chronic  
24 inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev 2013: published  
25 online 30 December 2013, doi: 10.1002/14651858.CD001797.pub3.  
26  
27

28 \*\* This paper is a metaanalysis of the clinical studies with IVIg conducted in patients with CIDP  
29  
30

31  
32 [63] Daniel GW, Menis M, Sridhar G, et al. Immune globulins and thrombotic adverse events as  
33 recorded in a large administrative database in 2008 through 2010. Transfusion 2012;52:2113–21.  
34  
35

36  
37 [64] Mizrahi M. The hypercoagulability of intravenous immunoglobulin. Clin Adv Hematol Oncol  
38 2011;9:49–50  
39  
40

41  
42 [65] Caress JB, Houston-Webb L, Passmore LV, et al. Case-control study of thromboembolic events  
43 associated with IV immunoglobulin. J Neurol 2009;256:339–42.  
44  
45

46  
47 [66] Al-Riyami AZ, Lee J, Connolly M, Shereck E. Cerebral sinus thrombosis following IV  
48 immunoglobulin therapy of immune thrombocytopenic purpura. Pediatr Blood Cancer  
49 2011;57:157–9.  
50  
51

52  
53 [67] Huang L, Kanellis J, Mulley W. Slow and steady. Reducing thrombotic events in renal  
54 transplant recipients treated with IVIg for antibody-mediated rejection. Nephrology 2011;16:239–  
55 42.  
56  
57  
58  
59  
60

1 [68] Rachid R, Bonilla FA. The role of anti-IgA antibodies in causing adverse reactions to gamma  
2 globulin infusion in immunodeficient patients: a comprehensive review of the literature. *J Allergy*  
3 *Clin Immunol* 2012;129:628–34.  
4  
5  
6

7  
8 [69] Morgan S, Sorensen P, Vercellotti G, et al. Haemolysis after treatment with intravenous  
9 immunoglobulin due to anti-A. *Transfus Med* 2011;21:267–70.  
10  
11

12  
13 **[70] Nguyen TP, Biliciler S, Wahed A et al. Occurrence of hemolytic anemia in patients with**  
14 **GBS treated with high-dose IVIg. *Neurol Neuroimmunol Neuroinflammation*: published**  
15 **online 11 December 2014, doi: 10.1212/NXI.0000000000000050**  
16  
17  
18

19  
20 [71] Welles CC, Tamba S, Lafayette RA. Hemoglobinuria and acute kidney injury requiring  
21 hemodialysis following intravenous immunoglobulin infusion. *Am J Kidney Dis* 2010;55:148–51.  
22  
23

24  
25 [72] Baxley A, Akhatari M. Hematologic toxicities associated with intravenous immunoglobulin  
26 therapy. *Int Immunopharmacol* 2011;11:1663-67  
27  
28

29  
30 **[73] Lewis M, Maddison P. Intravenous immunoglobulin causing reversible posterior**  
31 **leukoencephalopathy syndrome? *J Neurol Neurosurg Psychiatry* 2000;69:704**  
32  
33

34  
35 **[74] Doss-Esper CE, Singhal AB, Smith MS et al. Reversible posterior leukoencephalopathy,**  
36 **cerebral vasoconstriction, and strokes after intravenous immune globulin therapy in guillain-**  
37 **barre syndrome. *J Neuroimaging* 2005;15(2):188-92**  
38  
39

40  
41 **[75] Belmouaz S, Desport E, Leroy F et al. Posterior reversible encephalopathy induced by**  
42 **intravenous immunoglobulin. *Nephrol Dial Transplant* 2008;23(1):417-9**  
43  
44

45  
46 **[76] Stetefeld HR, Lehmann HC, Fink GR et al. Posterior reversible encephalopathy**  
47 **syndrome and stroke after intravenous immunoglobulin treatment in Miller-Fisher**  
48 **syndrome/Bickerstaff brain stem encephalitis overlap syndrome. *J Stroke Cerebrovasc Dis*:**  
49 **published online 20 August 2014, doi: 10.1016/j.jstrokecerebrovasdis**  
50  
51  
52

53  
54  
55 [77] Erdman DD, Anderson BC, Torok TJ, Finkel TH, Anderson LJ. A possible transmission of  
56 parvovirus B19 from intravenous immune globulin. *J Med Virol* 1997;53:233–6.  
57  
58  
59  
60

1  
2 [78] Sejvar JJ, Baughman AL, Wise M et al. Population incidence of Guillain-Barre syndrome: a  
3 systematic review and metaanalysis. *Neuroepidemiol* 2011;36:123-33  
4

5  
6 [79]\* van den Berg B, Walgaard C, Drenthen J, et al. Guillain-Barre syndrome: pathogenesis,  
7 diagnosis, treatment and prognosis. *Nature Rev* 2014;10:469-82  
8  
9

10 \*This article is a review on GBS  
11

12  
13 [80]\*\* Mathey EK, Park SB, Hughes RAC, et al. Chronic inflammatory demyelinating  
14 polyradiculoneuropathy: from pathology to phenotype. *J Neurol Neurosurg Psychiatry*  
15 2015;86:973–85  
16  
17

18 \*\*This paper gives insight into CIDP pathomechanism  
19

20  
21 [81] Yuki N, Hartung HP. Guillain-Barre syndrome. *N Engl J Med* 2012;366:2294–304  
22  
23

24  
25 [82] Arcila-Londono X, Lewis RA. Guillain-Barre syndrome. *Semin Neurol* 2012;32:179–186  
26  
27

28 [83] Yuki N. Guillain-Barre syndrome and anti-ganglioside antibodies: a clinician-scientist's  
29 journey. *Proc Jpn Acad Ser B Phys Biol Sci* 2012;88:299–326.  
30  
31

32  
33 [84] Caudie C, Quittard Pinon A, Taravel D, et al. Preceding infections and anti-ganglioside  
34 antibody profiles assessed by a dot immunoassay in 306 French Guillain-Barre syndrome patients. *J*  
35 *Neurol* 2011;258:1958–64  
36  
37

38  
39 [85] Sekiguchi Y, Uncini A, Yuki N, et al. Antiganglioside antibodies are associated with axonal  
40 Guillain-Barre syndrome: a Japanese-Italian collaborative study. *J Neurol Neurosurg Psychiatry*  
41 2012;83:23–8  
42  
43  
44

45  
46 [86] Ito M, Matsuno K, Sakumoto Y, et al. Ataxic Guillain-Barre syndrome and acute sensory ataxic  
47 neuropathy form a continuous spectrum. *J Neurol Neurosurg Psychiatry* 2011;82:294–99  
48  
49

50  
51 [87] Devaux JJ. Antibodies to gliomedin cause peripheral demyelinating neuropathy and the  
52 dismantling of the nodes of Ranvier. *Am J Pathol* 2012;181:1402–13  
53  
54

55  
56 [88] Ng JK, Malotka J, Kawakami N et al. Neurofascin as a target for autoantibodies in  
57 peripheral neuropathies. *Neurology* 2012;79(23):2241-8  
58  
59  
60

1  
2  
3 **[89] Prüss H, Schwab JM, Derst C et al. Neurofascin as target of autoantibodies in Guillain-**  
4 **Barre syndrome. Brain 2011; published online 27 January 2011, doi: 10.1093/brain/awq372**  
5  
6

7  
8 [90] Devaux JJ, Odaka M, Yuki N. Nodal proteins are target antigens in Guillain-Barre syndrome. J  
9 Peripher Nerv Syst 2012;17:62–71.  
10

11  
12 **[91] Chi L, Wang H, Zhang Y et al. Abnormality of circulating CD4+CD25+ regulatory T cell**  
13 **in patients with Guillain-Barré syndrome. J Neuroimmun 2007;192:206-14**  
14  
15

16  
17 **[92] Maddur MS, Rabin M, Hegde P et al. Intravenous immunoglobulin exerts reciprocal**  
18 **regulation of Th1/Th17 cells and regulatory T cells in Guillain-Barré syndrome patients.**  
19 **Immunol res 2014;60:320-9**  
20  
21

22  
23 **[93] Li S, Jin t, Zhang HL et al. Circulating Th17, Th22, and Th1 cells are elevated in the**  
24 **Guillain-Barré syndrome and downregulated by IVIg treatments. Mediators Inflamm 2014;**  
25 **published online 12 May 2014, doi: 10.1155/2014/740947**  
26  
27

28  
29 **[94] Lehmann HC, Hartung HP. Plasma exchange and intravenous immunoglobulins:**  
30 **mechanism of action in immune-mediated neuropathies. J Neuroimmunol 2011; 231:61-9**  
31  
32

33  
34 **[95] Mausberg AK, Dorok M, Stettner M et al. Recovery of the T-cell repertoire in CIDP by IV**  
35 **immunoglobulins. Neurology 2013;80(3):296-303**  
36  
37

38  
39 [96] Bril V, Ilse WK, Pearce R, et al. Pilot trial of immunoglobulin versus plasma exchange in  
40 patients with Guillain-Barré syndrome. Neurology 1996;46(1):100–3  
41  
42

43  
44 [97] Diener HC, Haupt WF, Kloss TM, et al. A preliminary, randomized, multicenter study  
45 comparing intravenous immunoglobulin, plasma exchange, and immune absorption in Guillain-  
46 Barré syndrome. European Neurology 2001;46(2):107–9  
47  
48

49  
50 [98] El-Bayoumi MA, El-Refaey AM, Abdelkader AM, et al. Comparison of intravenous  
51 immunoglobulin and plasma exchange in treatment of mechanically ventilated children with  
52 Guillain Barré syndrome: a randomized study. Critical Care (London, England) 2011;15(4):R164  
53  
54  
55  
56  
57  
58  
59  
60

1  
2 [99] Gürses N, Uysal S, Çetinkaya F, et al. Intravenous immunoglobulin treatment in children with  
3 Guillain-Barré syndrome. *Scandinavian Journal of Infectious Diseases* 1995;27(3):241–3  
4

5  
6 [100] Korinthenberg R, Schessl J, Kirschner J, et al. Intravenously administered immunoglobulin in  
7 the treatment of childhood Guillain-Barré syndrome: a randomized trial. *Pediatrics* 2005;116(1):8–  
8  
9 14  
10

11  
12 [101] Nomura K, Hamaguchi K, Hosokawa T, et al. A randomized controlled trial comparing  
13 intravenous immunoglobulin and plasmapheresis in Guillain-Barré syndrome. *Neurological*  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

[102] PSGBS Study Group. Randomised trial of plasma exchange, intravenous immunoglobulin,  
and combined treatments in Guillain-Barré syndrome. *Lancet* 1997;349(9047):225–30

[103] van der Meché FGA, Schmitz PIM. Dutch Guillain-Barré Study Group. A randomized trial  
comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. *New*  
*England J Medicine* 1992;326(17): 1123–9

[104] Wang R, Feng A, Sun W, et al. Intravenous immunoglobulin therapy in children with  
Guillain-Barré syndrome. *Journal of Applied Clinical Pediatrics* 2001;16(4): 223–4

[105] Hughes RA, Swan AV, van Doorn PA. Intravenous immunoglobulin for Guillain-Barré  
syndrome. *Cochrane Database Syst Rev.* 2014: published online 19 September 2014;9:CD002063,  
doi: 10.1002/14651858

[106] Mahdi-Rogers M, Hughes RA. Epidemiology of chronic inflammatory neuropathies in  
southeast England. *Eur J Neurol* 2014;21:28–33.

[107] Van den Bergh PY, Hadden RD, Bouche P, et al. EFNS/PNS guideline on management of  
chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the  
EFNS and the PNS—first revision. *Eur J Neurol* 2010;17:356–63.

[108] Viala K. Diagnosis of atypical forms of chronic inflammatory demyelinating  
polyradiculoneuropathy: a practical overview based on seom case studies. *Internat J Neurosci* 2015:  
published online 16 October 2015, doi: 10.3109/00207454.2015.1096786

1  
2  
3 [109] Schneider-Hohendorf T, Schwab N, Uceyler N, et al. CD8+ T-cell immunity in chronic  
4 inflammatory demyelinating polyradiculoneuropathy. *Neurology* 2012;78:402–8  
5  
6

7  
8 [110] Chi LJ, Wang HB, Wang WZ. Impairment of circulating CD4+CD25+ regulatory T cells in  
9 patients with chronic inflammatory demyelinating polyradiculoneuropathy. *J Peripher Nerv Syst*  
10 2008;13:54–63  
11  
12

13  
14 [111] Ng JK, Malotka J, Kawakami N, et al. Neurofascin as a target for autoantibodies in peripheral  
15 neuropathies. *Neurology* 2012;79:2241–8  
16  
17

18  
19 [112] Querol L, Nogales-Gadea G, Rojas-Garcia R, et al. Antibodies to contactin-1 in chronic  
20 inflammatory demyelinating polyneuropathy. *Ann Neurol* 2013;73:370–80  
21  
22

23  
24 [113] Cifuentes-Diaz C, Dubourg O, Irinopoulou T, et al. Nodes of Ranvier and paranodes in  
25 chronic acquired neuropathies. *PLoS ONE* 2011: published online 18 January 2011,  
26 doi:10.1371/journal.pone.0014533  
27  
28

29  
30 [114] Querol L, Nogales-Gadea G, Rojas-Garcia R, et al. Neurofascin IgG4 antibodies in CIDP  
31 associate with disabling tremor and poor response to IVIg. *Neurology* 2014;82:879–86  
32  
33

34  
35 [115] Miura Y, Devaux JJ, Fukami Y, et al. Contactin 1 IgG4 associated to chronic inflammatory  
36 demyelinating polyneuropathy with sensory ataxia. *Brain* 2015: published online 25 March 2015,  
37 doi: <http://dx.doi.org/10.1093/brain/awv054>  
38  
39  
40

41  
42  
43 **[116] Tackenberg B, Jelcic I, Baerenwaldt A et al. Impaired inhibitory Fcγ receptor IIB**  
44 **expression on B cells in chronic inflammatory demyelinating polyneuropathy. *PNAS***  
45 **2009;106:4788-92**  
46  
47

48  
49  
50 **[117] Bick S, Tschernatsch M, Karg A et al. Intravenous immunoglobulin inhibits BAFF**  
51 **production in chronic inflammatory demyelinating polyneuropathy - a new mechanism of**  
52 **action. *J Neuroimmunol* 2013;256:84-90**  
53  
54

55  
56  
57 **[118] Ritter C, Förster D, Albrecht P et al. IVIG regulates BAFF expression in patients with**  
58 **chronic inflammatory demyelinating polyneuropathy (CIDP). *J Neuroimmunol***  
59  
60



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**2014;274:225-9**

[119] Hughes RAC, Mehndiratta MM. Corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database of Syst Rev 2012: published online 19 September 2012, doi: 10.1002/14651858.CD002062.pub2

[120] Mehndiratta MM, Hughes RAC, Agarwal P. Plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev 2004: published online 2004, doi: 10.1002/14651858.CD003906.pub2.

[121] Hughes RAC, Bensa S, Willison HJ, et al. Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 2001;50:195–201

[122] Dyck PJ, Litchy WJ, Kratz KM, et al. A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 1994;36: 838–45

[123] Vermeulen M, van Doorn PA, Brand A, et al. Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy: a double blind, placebo controlled study. J Neurol Neurosurg Psychiatry 1993;56:36–39

[124] Mendell JR, Barohn RJ, Freimer ML, et al. Randomized controlled trial of IVIg in untreated chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 2001;56: 445–49

[125] Hahn AF, Bolton CF, Zochodne D, et al. Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy. A double-blind, placebo-controlled, cross-over study. Brain 1996;119:1067–77

[126] van Doorn PA, Brand A, Strengers PF, et al. High-dose intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: a double-blind, placebo-controlled, crossover study. Neurology 1990;40:209–12

[127] Eftimov F, Winer JB, Vermeulen M, et al. Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev 2009: published online 21 January 2009, doi:10.1002/14651858.CD001797.pub2

1  
2  
3 [128]\* Hughes RAC, Donofrio P, Brill V, et al. Intravenous immune globulin (10% caprylate  
4 chromatography purified) for the treatment of chronic inflammatory demyelinating  
5 polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial. *Lancet Neurol*  
6 2008;7:136-44  
7  
8

9  
10 \*This was a placebo-controlled clinical trial with IVIg conducted in CIDP patients  
11

12  
13 [129] Leger JM, De Bleecker JL, Sommer C, et al. Efficacy and safety of Privigen in patients with  
14 chronic inflammatory demyelinating polyneuropathy: results of a prospective, single-arm, open-  
15 label Phase III study (the PRIMA study). *J Periph Nervous Syst* 2013;18:130-40  
16  
17

18  
19 [130] Cocito D, Paolasso I, Antonini G, et al. A nationwide retrospective analysis on the effect of  
20 immune therapies in patients with chronic inflammatory demyelinating polyradiculoneuropathy *Eur*  
21 *J Neurol* 2010;17:289–94  
22  
23

24  
25 [131]\* Nobile-Orazio E, Cocito D, Jann S, et al. Intravenous immunoglobulin versus intravenous  
26 methylprednisolone for chronic inflammatory demyelinating polyradiculoneuropathy: a randomised  
27 controlled trial. *Lancet Neurol* 2012; 11:493–502  
28  
29

30  
31 \*This study compared IVIg to intravenous methylprednisolone in CIDP patients and found no  
32 significant differences  
33  
34

35  
36 [131] Vlam L, van der PolWL, Cats EA, et al. Multifocal motor neuropathy: diagnosis,  
37 pathogenesis and treatment strategies. *Nat Rev Neurol* 2012;8:48–58  
38  
39

40  
41 [132] Cats EA, Jacobs BC, Yuki N, et al. Multifocal motor neuropathy: association of anti-GM1  
42 IgM antibodies with clinical features. *Neurology* 2010;75:1961–7  
43  
44

45  
46 [133] Galban-Horcajo F, Fitzpatrick AM, Hutton AJ, et al. Antibodies to heteromeric glycolipid  
47 complexes in multifocal motor neuropathy. *Eur J Neurol* 2013;20:62–70  
48  
49

50  
51 [134] Notturmo F, Di FT, Yuki N, et al. Autoantibodies to neurofascin-186 and gliomedin in  
52 multifocal motor neuropathy. *J Neuroimmunol* 2014;276:207–12  
53  
54

55  
56 [135] Joint Task Force of the EFNS and the PNS. European Federation of Neurological  
57 Societies/Peripheral Nerve Society guideline on management of multifocal motor neuropathy.  
58  
59

1  
2 Report of a joint task force of the European Federation of Neurological Societies and the Peripheral  
3 Nerve Society—first revision. *J Peripher Nerv Syst* 2010;15:295–301  
4

5  
6  
7 [136] Cats EA, van der Pol WL, Piepers S, et al. Correlates of outcome and response to IVIg in 88  
8 patients with multifocal motor neuropathy. *Neurology* 2010;75:818–25  
9

10  
11  
12 [137] Piepers S, Jansen MD, Cats EA, et al. IVIg inhibits classical pathway activity and anti-GM1  
13 IgM-mediated complement deposition in MMN. *J Neuroimmunol* 2010;229:256–62  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## List of abbreviations

1		
2		
3		
4		
5		
6		
7	AIDP	acute inflammatory demyelinating polyneuropathy
8	AMAN	acute motor axonal neuropathy
9		
10	APC	antigen presenting cell
11		
12	C1q	complement 1q
13	CD22	cluster of differentiation-22
14		
15	CIDP	chronic inflammatory demyelinating polyneuropathy
16		
17	CMV	cytomegalovirus
18	CPA	cell-penetrating antibodies
19		
20	CSF	cerebrospinal fluid
21		
22	CTLA-4	cytotoxic T-lymphocyte-associated protein 4
23		
24	CXCL11	C-X-C motif chemokine 11
25	CXCL	chemokine (C-X-C motif) ligand
26		
27	DC	dendritic cell
28	EBV	Epstein-Barr virus
29		
30	EFNS	European Federation of Neurological Societies
31		
32	ELAM-1	endothelial-leukocyte adhesion molecule-1
33	ENG	electroneurography
34		
35	Fab	variable region
36	Fc	constant fragment
37		
38	Fc $\gamma$ R	Fc $\gamma$ receptor
39		
40	FcRn	neonatal Fc receptor
41		
42	FCRL3	Fc receptor-like protein 3
43		
44	FOXP3	transcription factor, forkhead box P3
45	GARP	glycoprotein A repetitions predominantand
46		
47	GBS	Guillain-Barre syndrome
48		
49	HLA-DR	human leukocyte antigen-DR
50		
51	ICAM	intercellular adhesion molecule
52	IFN $\gamma$	interferon- $\gamma$
53		
54	IgG	immunoglobulin G
55	INCAT	Inflammatory Neuropathy Cause and Treatment
56		
57	ITAM	immunoreceptor tyrosine-based activation motif
58		
59	ITIM	intracellular immunoreceptor tyrosine-based inhibitory motif
60		

1		
2	ITP	immune thrombocytopenic purpura
3	IVIg	intravenous immunoglobulin
4		
5	MAC	membrane attack complex
6		
7	MFS	Miller Fisher syndrome
8		
9	MHC	major histocompatibility complex
10		
11	MMN	multifocal motor neuropathy
12	MRC	Medical Research Council sum score.
13		
14	NF186	neurofascin 186
15	NK cells	natural killer cells
16		
17	PD-L1	Programmed death-ligand 1
18		
19	RCT	randomized-controlled trial
20		
21	SIGLEC	sialic acid-binding immunoglobulin-like lectin
22	SIGN	specific intercellular adhesion molecule-3-grabbing non-integrin
23		
24	T1/2	half-life
25	TCR	T cell receptor
26		
27	TGF-1	transforming growth factor-1
28		
29	Th1	T helper cell 1
30	Th17	T helper cell 17
31		
32	TIGIT	T cell immunoreceptor with Ig and ITIM domains
33		
34	TNF $\alpha$	tumor necrosis factor- $\alpha$
35	Treg	regulatory T cell
36		
37	VCAM-1	vascular cell adhesion molecule-1
38		
39		
40		
41		
42		
43		
44		
45		
46		
47		
48		
49		
50		
51		
52		
53		
54		
55		
56		
57		
58		
59		
60		

**Bullets**

- IVIg is a blood product obtained from plasma pooled from thousands of healthy donors. IVIg is used in lower doses as a replacement therapy for immunodeficient patients and in doses of 1-2 g/kg for the suppression of autoimmune diseases. Besides the licensed indications, several *off-label* indications exist.
- IVIg has a complex mechanism of action, involving the neutralization and an enhanced clearance of pathological antibodies, Fc receptor blockade, complement inhibition, a decrease in the production of inflammatory cytokines, immunoregulation of DCs, B and T cells, an enhancement of Tregs, and the modulation of apoptosis.
- IVIg is generally well tolerated, with most of the side effects being mild and transient. Severe side effects, such as thrombosis, anaphylactic reaction, and kidney injury, can occur.
- Immune-mediated polyneuropathies are a heterogeneous group of diseases of the peripheral nervous system. Anti-ganglioside antibodies through molecular mimicry and complement activation play a role in the pathomechanism of GBS. The pathomechanism of CIDP is not fully understood, with both cellular and humoral mechanisms involved. Several clinical trials prove the efficacy and safety of IVIg in GBS and CIDP.
- Despite the considerable progress in both the supportive therapy and immunotherapy, GBS is still a life-threatening disease, resulting in a permanent disability in some 20% of the patients. The chronic forms are difficult to diagnose, and, especially in the case of a delay in the initiation of the therapy, a severe disability and an impairment of the quality of life can ensue. There is still much to do in order to improve the therapy for immune-mediated polyneuropathies.
- Understanding the exact mechanism of action of IVIg in these disorders might enable the design of more specific therapies.

Dear Mr David Owusu,

We have revised our manuscript entitled '**Intravenous immunoglobulin: pharmacological properties and use in polyneuropathies**' in accordance with the comments of the reviewers. We are pleased to accept all the suggestions.

Some aspects that were only shortly discussed or were not included in the original manuscript, either due to lack of space or other considerations, have now been discussed in the revised manuscript, along the recommendations of the reviewers. These supplementations considerably extended the length of the manuscript. Several new references have been added as suggested by the reviewers. The changes made in the text and the new references are highlighted in bold red letters. Hereby we provide a point-wise rebuttal to the comments of the editorial office and reviewers:

#### Comments of the editorial office:

*1. Please can you confirm whether your figures and tables are original and have not previously been published, OR, provide me with a copy of permission to use from the original publisher. For any figures that require permission, please ensure that the figure caption is updated to acknowledge the source as per the original publisher's requirements*

We declare that the figures and tables are original and have been specially created for this article.

#### Reviewer comments

##### Reviewer 1

*General comments:*

*This article presents pharmacological properties and use o IGIV in polyneuropathies. This referee recommends augmenting the review by including the following references:*

*1. In Guillain-Barré syndrome patients, IGIV has been shown to modify T cell response*

- *PMID: 25391612;*
- *PMID: 24899787;*
- *PMID: 25482074;*
- *PMID: 17997492*

The effects of IVIg on T cell response are now discussed in the revised manuscript. The papers recommended have been included in the references of our manuscript.

*2. Fc sialylation- independent mechanisms of IGIV merits discussion and referencing*

- *PMID: 25982320;*
- *PMID: 25012067;*
- *PMID: 25352126;*
- *PMID: 24760152;*
- *PMID: 24700174*

A new paragraph has now been included on the Fc sialylation-independent mechanisms of action of IVIg. The papers recommended have been included in the references of the revised manuscript.

##### Reviewer 2

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

*General comments:*

*The paper is a review about the use and mechanisms of action of IVIg in immune mediated neuropathies. Generally the paper is well written and acceptable in length.*

*My main concern is that some aspects are not discussed in detail that includes also the discussion of relevant references that are not included in this version. So I strongly recommend addressing the following points:*

*1. page 5: Dimers are can also occur after IVIg infusion due to idiotypic.anti-idiotypic antibodies. A shot paragraph is needed here that include the following references:*

*• Schaub A, Wymann S, Heller M, Ghielmetti M, Belezny Z, Stadler BM, Bolli R, Miescher S. Self-reactivity in the dimeric intravenous immunoglobulin fraction. *Ann N Y Acad Sci.* 2007 Sep;1110:681-93. PubMed PMID: 17911483.*

*• Ritter C, Bobylev I, Lehmann HC. Chronic inflammatory demyelinating polyneuropathy (CIDP): change of serum IgG dimer levels during treatment with intravenous immunoglobulins. *J Neuroinflammation.* 2015 Aug 14;12:148. doi: 10.1186/s12974-015-0361-1. PubMed PMID: 26268846; PubMed Central PMCID: PMC4535537.*

*• Tankersley DL. Dimer formation in immunoglobulin preparations and speculations on the mechanism of action of intravenous immune globulin in autoimmune diseases. *Immunol Rev.* 1994 Jun;139:159-72. Review. PubMed PMID: 7927410.*

A paragraph has been included on dimer formation following IVIg infusion. The recommended papers are now cited in the revised manuscript.

*2. Page 6: It is Guillain-Barré syndrome*

The spelling has been corrected throughout the manuscript.

*3. Page 10: Martin at el. needs a reference*

A reference has been added

*4. Page 11: IgA: I would change this sentence because in the newer IVIG preparations this problem is not prevalent anymore.*

This sentence has been changed accordingly.

*5. Page 11: Safety considerations:*

*• This paper need to be referenced as well (hemolytic anemia after IVIG in non-O blood types) O <http://nn.neurology.org/content/1/4/e50.short?sid=b6345c13-f62b-4d0b-a3e8-2a866bf7a43e>*

This paper has been discussed in the revised manuscript and has been added to the reference list.

*• PRES may occasionally occur after IVIg infusion. This needs to be added (also in the table3)*

*• Stetefeld HR, Lehmann HC, Fink GR, Burghaus L. Posterior reversible encephalopathy syndrome and stroke after intravenous immunoglobulin treatment in Miller-Fisher syndrome/Bickerstaff brain stem encephalitis overlap syndrome. *J Stroke Cerebrovasc Dis.* 2014 Oct;23(9):e423-5. doi:*



- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13
- 10.1016/j.jstrokecerebrovasdis.2014.05.034. Epub 2014 Aug 20. PubMed PMID: 25149206.
- Belmouaz S, Desport E, Leroy F, Teynie J, Hannequin J, Ayache RA, Bridoux F, Touchard G. Posterior reversible encephalopathy induced by intravenous immunoglobulin. *Nephrol Dial Transplant*. 2008 Jan;23(1):417-9. Epub 2007 Oct 30. PubMed PMID: 17971381.
  - Doss-Esper CE, Singhal AB, Smith MS, Henderson GV. Reversible posterior leukoencephalopathy, cerebral vasoconstriction, and strokes after intravenous immune globulin therapy in guillain-barre syndrome. *J Neuroimaging*. 2005 Apr;15(2):188-92. PubMed PMID: 15746232.
  - Lewis M, Maddison P. Intravenous immunoglobulin causing reversible posterior leukoencephalopathy syndrome? *J Neurol Neurosurg Psychiatry*. 2000 Nov;69(5):704. PubMed PMID: 11184238; PubMed Central PMCID: PMC1763438.

14 This possible side effect is now discussed in the revised manuscript and has been mentioned in  
15 Table 3. The above papers have all been included in the references.  
16

17  
18  
19  
20  
21  
22

6. Page 13: It is correct that nodal protein has been identified. However the frequency of nodal protein abs is much less compared to anti-ganglioside antibodies (around 4%). Please align and include the following references

- Ng JK, Malotka J, Kawakami N, Derfuss T, Khademi M, Olsson T, Linington C, Odaka M, Tackenberg B, Prüss H, Schwab JM, Harms L, Harms H, Sommer C, Rasband MN, Eshed-Eisenbach Y, Peles E, Hohlfeld R, Yuki N, Dornmair K, Meinl E. Neurofascin as a target for autoantibodies in peripheral neuropathies. *Neurology*. 2012 Dec 4;79(23):2241-8. doi: 10.1212/WNL.0b013e31827689ad. Epub 2012 Oct 24. PubMed PMID: 23100406; PubMed Central PMCID: PMC3542349.
- Prüss H, Schwab JM, Derst C, Görtzen A, Veh RW. Neurofascin as target of autoantibodies in Guillain-Barre syndrome. *Brain*. 2011 May;134(Pt 5):e173; author reply e174. doi: 10.1093/brain/awq372. Epub 2011 Jan 27. PubMed PMID: 21278083.

23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36

A new paragraph on antibodies against nodal proteins has been constructed. The suggested references have been included.

37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49

7. Page 14: I do not agree with the statement that the therapeutic action of IVIG in GBS is mainly attributed to the reduction of pathological autoantibodies through anti-idiotypes. Other mechanisms are considered of equal importance. References that need to be included here are:

- Mausberg AK, Dorok M, Stettner M, Müller M, Hartung HP, Dehmel T, Warnke C, Meyer Zu Hörste G, Kieseier BC. Recovery of the T-cell repertoire in CIDP by IV immunoglobulins. *Neurology*. 2013 Jan 15;80(3):296-303. doi: 10.1212/WNL.0b013e31827debad. Epub 2012 Dec 26. PubMed PMID: 23269592.
- Lehmann HC, Hartung HP. Plasma exchange and intravenous immunoglobulins: mechanism of action in immune-mediated neuropathies. *J Neuroimmunol*. 2011 Feb;231(1-2):61-9. doi: 10.1016/j.jneuroim.2010.09.015. Epub 2010 Nov 5. Review. PubMed PMID: 21056913.

50  
51  
52  
53

The section on the therapeutic action of IVIg in GBS has been considerably modified along the Reviewer's observation, and the suggested references are now included in the manuscript.

54  
55  
56  
57  
58  
59  
60

8. Page 16: Again I do not agree that the effect is mainly mediated by anti-idiotypic antibodies. This is not substantiated by experimental studies since the targets for autoantibodies in CIDP are largely unknown. A more detailed paragraph about the MoFA of IVIg in CIDP is needed:

- Regulation of Fc receptors: Tackenberg B, Jelcic I, Baerenwaldt A, Oertel WH, Sommer N, Nimmerjahn F, Lünemann JD. Impaired inhibitory Fcγ receptor IIB expression on B cells in

1  
2 *chronic inflammatory demyelinating polyneuropathy. PNAS*

3  
4 The section on the therapeutic action of IVIg in CIDP has been considerably modified accordingly,  
5 including the effect on Fc receptors. The recommended references have been included.  
6  
7

8 *Anti-cytokine antibodies (BAFF/APRIL):*

9  
10 • *IVIg regulates BAFF expression in patients with chronic inflammatory demyelinating*  
11 *polyneuropathy (CIDP). Ritter C, Förster D, Albrecht P, Hartung HP, Kieseier BC, Lehmann HC. J*  
12 *Neuroimmunol. 2014 Sep 15;274(1-2):225-9. doi: 10.1016/j.jneuroim.2014.06.007.*

13 • *Intravenous immunoglobulin inhibits BAFF production in chronic inflammatory demyelinating*  
14 *polyneuropathy - a new mechanism of action Bick S, Tschernatsch M, Karg A, Fuehlhuber V,*  
15 *Trenczek TE, Faltermeier K, Hackstein H, Kaps M, Blaes F. J Neuroimmunol. 2013 Mar 15;256(1-*  
16 *2):84-90. doi: 10.1016/j.jneuroim.2013.01.001.*

17 • *Plasma exchange and intravenous immunoglobulins: mechanism of action in immune-mediated*  
18 *neuropathies. Lehmann HC, Hartung HP. J Neuroimmunol. 2011 Feb;231(1-2):61-9. Doi: 10*  
19

20  
21 The part on the therapeutic action of IVIg in CIDP has been rewritten accordingly, including the  
22 effect on BAFF and other cytokines. The recommended references have been included.  
23

24  
25 *Table 2: anti-cytokine abs have to be included*

26  
27 Anti-cytokine abs are now included in Table 2.  
28  
29

### 30 **Reviewer 3**

31 *Specific comments:*

32  
33  
34 *1. The pharmacodynamic mechanism of action section needs to cite more recent references.*

35  
36 The section on pharmacodynamics and mechanism of action has been improved and new references  
37 have been added.  
38

39  
40  
41 *2. The recent advances in Intravenous immunoglobulin preparation needs to be discussed*  
42 *thoroughly.*

43  
44 The revised manuscript has been supplemented with a new paragraph on the advances in IVIg  
45 preparation.  
46

47  
48  
49 *3. Dosage regimen of Intravenous immunoglobulin for immune deficiency syndrome needs to be*  
50 *included.*

51  
52 The revised manuscript now includes the dose and therapeutic regimen of IVIg therapy for  
53 immunodeficiency syndrome.  
54

55  
56  
57 *4. Storage condition and safety consideration for handling of immunoglobulin preparation needs to*  
58 *be included.*  
59  
60

1  
2 Storage conditions and special considerations as regards the handling of IVIg preparations are now  
3 discussed in the revised manuscript.  
4

5  
6 *5. The authors need to justify the use of IVIg over other Ig products.*  
7

8 The manuscript has been supplemented with a new paragraph discussing factors influencing the  
9 choice for the route of administration.  
10

11  
12 *6. Pathophysiological mechanism of polyneuropathy needs to be explained in more detail.*  
13

14 The chapters discussing the pathophysiological mechanisms of polyneuropathies have been  
15 considerable modified and improved and is explained in more detail.  
16  
17

18  
19 We are grateful to the Reviewers for their efforts put into our manuscript, which we feel has led to a  
20 considerable overall improvement.  
21

22 We hope that the revised manuscript in its current form will be deemed suitable for publication.  
23

24 Yours sincerely,  
25

26 László Vécsei  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



## PUBLISHING AGREEMENT

This is an agreement under which you, the author, assign copyright in your article to Informa UK Limited registered in England under no. 1072954 trading as Taylor & Francis Group, Registered Office: 5 Howick Place, London SW1P 1WG (hereinafter 'Taylor & Francis') to allow us to publish your article, including abstract, tables, figures, data, and supplemental material hosted by us, as the Version of Record (VoR) in the Journal for the full period of copyright throughout the world, in all forms and all media, subject to the Terms & Conditions below.

Please read this agreement carefully, complete it, and return a copy to us by email, fax, or hard copy immediately, to avoid any delay in the publication of your article.

Postal address: Taylor & Francis Journals Production, 4 Park Square, Milton Park, Abingdon OX14 4RN, UK

Fax: +44 (0) 207 017 6336 Email: [T&Fproduction@tandf.co.uk](mailto:T&Fproduction@tandf.co.uk)

ARTICLE TITLE: ('Article') INTRAVENOUS IMMUNOGLOBULIN: PHARMACOLOGICAL PROPERTIES AND USE IN POLYNEUROPATHIES  
 AUTHOR(S): LIVIA DEZSI, ZOLTAN HORVATH, LASZLO VECSEI  
 JOURNAL TITLE: Expert Opinion on Drug Metabolism & Toxicology ('Journal')

Please complete and sign below.

Please tick *either* box A or box B, **BUT NOT BOTH**

- A** I own copyright, and I am assigning copyright in my article to Taylor & Francis. In the case of a multi-authored article, I confirm that I am authorized by my co-authors to make this assignment as their agent on their behalf. The co-authors have agreed the priority of the assertion of copyright and the order of names in the publication of the article.
- B** I am a civil servant or an employee of a Government, Government Agency, International Organization, or Commercial Corporation which is granting a non-exclusive licence to publish the article and which hereby recognizes Taylor & Francis as the sole licensee for the publication of the final, definitive, and citable Version of Record (VoR). In the case of a multi-authored article, I confirm that I am authorized by my co-authors to enter into this licence as their agent on their behalf. The co-authors have agreed the priority of the assertion of copyright and the order of names in the publication of the article.

If you have ticked **B**, please indicate which of the statements below apply to you (and your co-authors):

- I am an employee of the UK, Canadian, Australian, or another Commonwealth Realm Government, and the Crown retains and asserts copyright.
- I am a US Government (including NIH) employee and there is no copyright to transfer.
- I am a contractor of the US Government (includes NIH contractors) under contract number: \_\_\_\_\_
- I am an employee of the European Commission and copyright is asserted and retained by the European Union.
- I am an employee of the World Bank and copyright is asserted and retained by that entity.
- I am an employee of the Food & Agricultural Organization and copyright is asserted and retained by that entity.
- I am an employee of a Government, Agency, or International Organization and copyright is retained by that entity. Name of entity: \_\_\_\_\_
- I am employed and the copyright belongs to my employer (or is a 'work made for hire' under US law). Name of corporation: \_\_\_\_\_

## ASSIGNMENT OF COPYRIGHT

I hereby assign Taylor & Francis with full title guarantee all rights of copyright and related publishing rights in my article, in all forms and all media (whether known at this time or developed at any time in the future) throughout the world, in all languages, where our rights include but are not limited to the right to translate, create adaptations, extracts, or derivative works and to sublicense such rights, for the full term of copyright (including all renewals and extensions of that term), to take effect if and when the article is accepted for publication.

I confirm that I have read and accept the full Terms & Conditions below including my author warranties, and have read and agree to comply with the Journal's policies on **peer review** and **publishing ethics**.

Signed: ..... Name (Print): László Vecsei

Position: PRF ..... Date: 27/7/2016

**THIS FORM IS A LEGALLY BINDING DOCUMENT. WE RECOMMEND THAT YOU RETAIN A COPY OF IT AND CONSULT A LEGAL ADVISOR IF YOU HAVE ANY QUESTIONS.**

## ASSIGNMENT OF COPYRIGHT: TERMS &amp; CONDITIONS

## DEFINITION

1. Your article is defined as comprising (a) your Accepted Manuscript (AM) in its final form; (b) the final, definitive, and citable Version of Record (VoR) including the abstract, text, bibliography, and all accompanying tables, illustrations, data, and media; and (c) any supplemental material hosted by Taylor & Francis. This assignment and these Terms & Conditions constitute the entire agreement and the sole understanding between you and us ('agreement'); no amendment, addendum, or other communication will be taken into account when interpreting your and our rights and obligations under this agreement, unless amended by a written document signed by both of us.

## TAYLOR &amp; FRANCIS' RESPONSIBILITIES

2. If deemed acceptable by the Editors of the Journal, we shall prepare and publish your article in the Journal. We may post your accepted manuscript in advance of the formal publication of the VoR. We reserve the right to make such editorial changes as may be necessary to make the article suitable for publication, or as we reasonably consider necessary to avoid infringing third-party rights or breaching any laws; and we reserve the right not to proceed with publication for whatever reason.
3. Taylor & Francis will deposit your Accepted Manuscript (AM) to any designated institutional repository including PubMedCentral (PMC) with which Taylor & Francis has an article deposit agreement; see 4 iv (a) below.

## RIGHTS RETAINED BY YOU AS AUTHOR

4. These rights are personal to you, and your co-authors, and cannot be transferred by you to anyone else. Without prejudice to your rights as author set out below, you undertake that the fully reference-linked VoR will not be published elsewhere without our prior written consent. You assert and retain the following rights as author(s):
  - i. The right to be identified as the author of your article, whenever and wherever the article is published, such rights including moral rights arising under § 77, Copyright, Designs & Patents Act 1988, and, so far as is legally possible, any corresponding rights we may have in any territory of the world.
  - ii. The right to retain patent rights, trademark rights, or rights to any process, product or procedure described in your article.
  - iii. The right to post and maintain at any time the Author's Original Manuscript (AOM; your manuscript in its original and unrefereed form; a 'preprint').
  - iv. The right to post at any time after publication of the VoR your AM (your manuscript in its revised after peer review and accepted for publication form; a 'postprint') as a digital file on your own personal or departmental website, provided that you do not use the VoR published by us, and that you include any amendments or deletions or warnings relating to the article issued or published by us; and with the acknowledgement: 'The Version of Record of this manuscript has been published and is available in <JOURNAL TITLE> <date of publication> <http://www.tandfonline.com/<Article DOI>>'
    - a) Please note that embargoes apply with respect to posting the AM to an institutional or subject repository. For further information, please see our list of journals with applicable embargo periods: [PDF](#) | [Excel](#). For the avoidance of doubt, you are not permitted to post the final published paper, the VoR published by us, to any site, unless it has been published as Open Access on our website.
    - b) If, following publication, you or your funder pay an Article Publishing Charge for retrospective Open Access publication, you may then opt for one of three licences: CC BY, CC BY-NC, or CC BY-NC-ND; if you do not respond, we shall assign a CC BY licence. All rights in the article will revert to you as author.
  - v. The right to share with colleagues copies of the article in its published form as supplied to you by Taylor & Francis as a digital eprint or printed reprint on a non-commercial basis.
  - vi. The right to make printed copies of all or part of the article on a non-commercial basis for use by you for lecture or classroom purposes provided that such copies are not offered for sale or distributed in any systematic way, and provided that acknowledgement to prior publication in the Journal is given.
  - vii. The right, if the article has been produced within the scope of your employment, for your employer to use all or part of the article internally within the institution or company on a non-commercial basis provided that acknowledgement to prior publication in the Journal is given.
  - viii. The right to include the article in a thesis or dissertation that is not to be published commercially, provided that acknowledgement to prior publication in the Journal is given.
  - ix. The right to present the article at a meeting or conference and to distribute printed copies of the article to the delegates attending the meeting provided that this is not for commercial purposes and provided that acknowledgement to prior publication in the Journal is given.
  - x. The right to use the article in its published form in whole or in part without revision or modification in personal compilations, or other publications of your own work, provided that acknowledgement to prior publication in the Journal is given.
  - xi. The right to expand your article into book-length form for publication provided that acknowledgement to prior publication in the Journal is made explicit (see below). Where permission is sought to re-use an article in a book chapter or edited collection on a commercial basis a fee will be due, payable by the publisher of the new work. Where you as the author of the article have had the lead role in the new work (i.e., you are the author of the new work or the editor of the edited collection), fees will be waived. Acknowledgement to prior publication in the Journal should be made explicit (see below):

**Acknowledgement:** This <chapter or book> is derived in part from an article published in <JOURNAL TITLE> <date of publication> <copyright Taylor & Francis>, available online: <http://www.tandfonline.com/<Article DOI>>

If you wish to use your article in a way that is not permitted by this agreement, please contact [permissionrequest@tandf.co.uk](mailto:permissionrequest@tandf.co.uk)

## WARRANTIES MADE BY YOU AS AUTHOR

5. You warrant that:
  - i. All persons who have a reasonable claim to authorship are named in the article as co-authors including yourself, and you have not fabricated or misappropriated anyone's identity, including your own.
  - ii. You have been authorized by all such co-authors to sign this agreement as agent on their behalf, and to agree on their behalf the priority of the assertion of copyright and the order of names in the publication of the article.
  - iii. The article is your original work, apart from any permitted third-party copyright material you include, and does not infringe any intellectual property rights of any other person or entity and cannot be construed as plagiarizing any other published work, including your own published work.
  - iv. The article is not currently under submission to, nor is under consideration by, nor has been accepted by any other journal or publication, nor has been previously published by any other journal or publication, nor has been assigned or licensed by you to any third party.
  - v. The article contains no content that is abusive, defamatory, libellous, obscene, fraudulent, nor in any way infringes the rights of others, nor is in any other way unlawful or in violation of applicable laws.
  - vi. Research reported in the article has been conducted in an ethical and responsible manner, in full compliance with all relevant codes of experimentation and legislation. All articles which report *in vivo* experiments or clinical trials on humans or animals must include a written statement in the Methods section that such work was conducted with the formal approval of the local human subject or animal care committees, and that clinical trials have been registered as applicable legislation requires.
  - vii. Any patient, service user, or participant (or that person's parent or legal guardian) in any research or clinical experiment or study who is described in the article has given written consent to the inclusion of material, text or image, pertaining to themselves, and that they acknowledge that they cannot be identified via the article and that you have anonymized them and that you do not identify them in any way. Where such a person is deceased, your warrant you have obtained the written consent of the deceased person's family or estate.
  - viii. You have complied with all mandatory laboratory health and safety procedures in the course of conducting any experimental work reported in your article; your article contains all appropriate warnings concerning any specific and particular hazards that may be involved in carrying out experiments or procedures described in the article or involved in instructions, materials, or formulae in the article; your article includes explicitly relevant safety precautions; and cites, if an accepted Standard or Code of Practice is relevant, a reference to the relevant Standard or Code.
  - ix. You have acknowledged all sources of research funding, as required by your research funder, and disclosed any financial interest or benefit you have arising from the direct applications of your research.
  - x. You have obtained the necessary written permission to include material in your article that is owned and held in copyright by a third party, which shall include but is not limited to any proprietary text, illustration, table, or other material, including data, audio, video, film stills, screenshots, musical notation and any supplemental material.
  - xi. You have read and complied with our policy on publishing ethics.
  - xii. You have read and complied with the Journal's Instructions for Authors.
  - xiii. You will keep us and our affiliates indemnified in full against all loss, damages, injury, costs and expenses (including legal and other professional fees and expenses) awarded against or incurred or paid by us as a result of your breach of the warranties given in this agreement.
  - xiv. You consent to allowing us to use your article for marketing and promotional purposes.

## GOVERNING LAW

6. This agreement (and any dispute, proceeding, claim or controversy in relation to it) is subject to English law and the parties hereby submit to the exclusive jurisdiction of the Courts of England and Wales.